

Review

Biological Activities and Secondary Metabolites from *Sophora tonkinensis* and Its Endophytic Fungi

Jia-Jun Liang^{1,2,†}, Pan-Pan Zhang^{1,2,†}, Wei Zhang^{1,2,†}, Da Song^{1,3}, Xin Wei^{1,2,*}, Xin Yin² , Yong-Qiang Zhou², Xiang Pu^{1,*} and Ying Zhou^{2,*}

¹ School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China

² School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China

³ School of Humanities and Management, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China

* Correspondence: sfweixin@163.com (X.W.); 18153114415@163.com (X.P.); yingzhou71@sina.com (Y.Z.)

† These authors contribute equally to this work.

Abstract: The roots of *Sophora tonkinensis* Gagnep., a traditional Chinese medicine, is known as Shan Dou Gen in the Miao ethnopharmacy. A large number of previous studies have suggested the usage of *S. tonkinensis* in the folk treatment of lung, stomach, and throat diseases, and the roots of *S. tonkinensis* have been produced as Chinese patent medicines to treat related diseases. Existing phytochemical works reported more than 300 compounds from different parts and the endophytic fungi of *S. tonkinensis*. Some of the isolated extracts and monomer compounds from *S. tonkinensis* have been proved to exhibit diverse biological activities, including anti-tumor, anti-inflammatory, antibacterial, antiviral, and so on. The research progress on the phytochemistry and pharmacological activities of *S. tonkinensis* have been systematically summarized, which may be useful for its further research.



Citation: Liang, J.-J.; Zhang, P.-P.; Zhang, W.; Song, D.; Wei, X.; Yin, X.; Zhou, Y.-Q.; Pu, X.; Zhou, Y.

Biological Activities and Secondary Metabolites from *Sophora tonkinensis* and Its Endophytic Fungi. *Molecules* **2022**, *27*, 5562. <https://doi.org/10.3390/molecules27175562>

Academic Editor: Gui-Guang Cheng

Received: 20 July 2022

Accepted: 25 August 2022

Published: 29 August 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: *S. tonkinensis*; phytochemistry; pharmacology; review

1. Introduction

Sophora tonkinensis Gagnep. belongs to the *Sophora* genus of the Leguminosae family, which is widely distributed in the southwest provinces of China [1,2]. As a famous folk medicine of the Miao people, the roots of *S. tonkinensis* were known as Shan Dou Gen or Guang Dou Gen in the Miao ethnopharmacy [3,4]. The early medicinal records of Shan Dou Gen were contained in the classics “*Kai Bao Ben Cao*”, in which *S. tonkinensis* showed the effect of anti-sore throat diseases [5,6]. A large number of previous studies have suggested the usage of *S. tonkinensis* in the folk treatment of upper respiratory tract infection, including lung and throat diseases. Meanwhile, *S. tonkinensis* is also highly effective in the treatment of liver and skin diseases [7,8]. Moreover, the roots of *S. tonkinensis* can also be combined with other medicines to form dozens of clinical and marketing Chinese patent medicines, such as *Kai Hou Jian throat spray*, *Shuyuanqing Spray*, and *Watermelon Frost Spray*, which is usually used for treatment of pharyngitis, tonsillitis, and aphthous ulcers [9–11]. Existing phytochemical works reported more than 300 compounds with various structural skeleton types from different parts and endophytic fungi of *S. tonkinensis*. Some of the isolated monomer compounds from *S. tonkinensis* have been proved to exhibit diverse biological activities, including anti-tumor, anti-inflammatory, antibacterial, antiviral, and so on [12–17]. Herein, the research progress on the phytochemistry and pharmacological activities of *S. tonkinensis* have been systematically summarized, which may be useful for its further research.

2. Phytochemistry

Previous studies have shown that alkaloids, flavonoids, triterpenoids, and triterpenoid saponins were the main chemical components isolated from *S. tonkinensis*. To date, 78 (1–78)

alkaloids, 115 (79–193) flavonoids, 46 (194–239) triterpenes and triterpenoid saponins, and 37 (240–276) other compounds have been isolated from *S. tonkinensis*, and it is worth mentioning that 40 (277–316) compounds were also isolated from the endophytic fungi produced by *S. Tonkinensis* (Table 1, Figure 1).

Table 1. The comprehensive list of the compounds from *S. tonkinensis* and its Endophytic fungus.

NO	Compounds	Molecular Formula	Parts of Plant	References
Matrine-Type alkaloids				
1	Matrine	C ₁₅ H ₂₄ N ₂ O	Roots	[12]
2	5 α ,14 β -Dihydroxymatrine	C ₁₅ H ₂₄ N ₂ O ₃	Roots	[12]
3	(+)-5 α -Hydroxyoxymatrine	C ₁₅ H ₂₄ N ₂ O ₃	Roots	[12]
4	(+)-Oxymatrine	C ₁₅ H ₂₄ N ₂ O ₂	Roots	[18]
5	(+)-5 α -Hydroxymatrine ((+)-Sophoranol)	C ₁₅ H ₂₄ N ₂ O ₂	Roots	[12]
6	(−)-14 β -Hydroxyoxymatrine	C ₁₅ H ₂₄ N ₂ O ₃	Roots	[18]
7	Sophtonseedline E	C ₁₇ H ₂₆ N ₂ O ₄	Seeds	[19]
8	Sophtonseedline F	C ₁₇ H ₂₈ N ₂ O ₃ S	Seeds	[19]
9	Sophtonseedline G	C ₁₅ H ₂₄ N ₂ O ₃	Seeds	[19]
10	Sophtonseedline H	C ₁₆ H ₂₆ N ₂ O ₂	Seeds	[19]
11	(+)-9 α -Hydroxymatrine	C ₁₅ H ₂₄ N ₂ O ₂	Seeds	[19]
12	(+)-5 α -9 α -Dihydroxymatrine	C ₁₅ H ₂₄ N ₂ O ₃	Seeds	[19]
13	(+)-Allomatrine (Sophoridine)	C ₁₅ H ₂₄ N ₂ O	Roots	[20]
14	(+)-Lehmannine	C ₁₅ H ₂₄ N ₂ O	Roots	[20]
15	(+)-12 α -Hydroxysophocarpine	C ₁₅ H ₂₄ N ₂ O ₂	Roots	[20]
16	(−)-13,14-Dehydrosophoridine (12,13-Dehydrosophoridine)	C ₁₅ H ₂₄ N ₂ O	Roots	[20]
17	(+)-5 α -Hydroxyoxysophocarpine	C ₁₅ H ₂₂ N ₂ O ₃	Roots	[14]
18	(−)-12 β -Hydroxyoxysophocarpine	C ₁₅ H ₂₂ N ₂ O ₃	Roots	[14]
19	(−)-12 β -Hydroxysophocarpine	C ₁₅ H ₂₂ N ₂ O ₂	Roots	[14]
20	(+)-Oxysophocarpine	C ₁₅ H ₂₂ N ₂ O ₂	Roots	[14]
21	Sophtonseedline B	C ₁₅ H ₂₂ N ₂ O ₃	Seeds	[19]
22	Sophtonseedline C	C ₁₇ H ₂₄ N ₂ O ₄	Seeds	[19]
23	Sophtonseedline D	C ₁₇ H ₂₆ N ₂ O ₃ S	Seeds	[19]
24	(−)-5 α -Hydroxysophocarpine (13,14-Dehydrosophoranol)	C ₁₅ H ₂₂ N ₂ O ₂	Seeds	[19]
25	(−)-9 α -Hydroxysophocarpine	C ₁₅ H ₂₂ N ₂ O ₂	Seeds	[19]
26	(−)-14 β -Acetoxymatrine	C ₁₇ H ₂₆ N ₂ O ₃	Leaves	[21]
27	(+)-14 α -Acetoxymatrine	C ₁₇ H ₂₆ N ₂ O ₃	Leaves	[21]
28	(−)-14 β -Hydroxymatrine	C ₁₅ H ₂₄ N ₂ O ₂	Leaves	[21]
29	(+)-14 α -Hydroxymatrine	C ₁₅ H ₂₄ N ₂ O ₂	Leaves	[21]
30	Sophtonseedline I	C ₁₇ H ₂₄ N ₂ O ₄	Seeds	[19]
31	6,7-Dehydro-matrine	C ₁₅ H ₂₂ N ₂ O	Seeds	[19]
32	5-Hydroxy-6,7-dehydro-matrine	C ₁₅ H ₂₂ N ₂ O ₂	Seeds	[19]
33	(+)-13,14-Dehydrosophoranol	C ₁₅ H ₂₂ N ₂ O ₂	Roots	[22]
34	(−)-Sophocarpine	C ₁₅ H ₂₂ N ₂ O	Roots	[12]
35	(+)-5 α -Hydroxylemannine	C ₁₅ H ₂₂ N ₂ O ₂	Roots	[14]
36	13 α -Hydroxymatrine	C ₁₅ H ₂₄ N ₂ O ₂	Roots	[23]
37	13 β -Hydroxymatrine	C ₁₅ H ₂₄ N ₂ O ₂	Roots	[23]
38	11,12-Dehydroallmatrine	C ₁₅ H ₂₂ N ₂ O	Roots	[1]
39	11,12-Dehydromatrine	C ₁₅ H ₂₂ N ₂ O	Roots	[1]
40	(+)-Matrine N-oxide	C ₁₅ H ₂₄ N ₂ O	Leaves	[21]
41	(+)-Sophoranol N-oxide	C ₁₅ H ₂₄ N ₂ O ₂	Leaves	[21]
42	(+)-7,11-Dehydromatrine	C ₁₅ H ₂₂ N ₂ O	Roots	[22]
43	Alopecurin A	C ₁₅ H ₂₂ N ₂ O ₄	Seeds	[19]
44	Sophtonseedline J	C ₁₅ H ₂₀ N ₂ O ₃	Seeds	[19]
45	Sophtonseedline K	C ₁₅ H ₂₀ N ₂ O ₃	Seeds	[19]
46	Sophtonseedline A	C ₁₅ H ₂₂ N ₂ O ₂	Seeds	[19]
47	5,6-Dehydro-matrine	C ₁₅ H ₂₂ N ₂ O	Seeds	[19]
48	Isosophocarpine	C ₁₅ H ₂₂ N ₂ O	Roots	[23]
49	(+)-Sophoramine (7 β -Sophoramine)	C ₁₅ H ₂₀ N ₂ O	Roots	[14]

Table 1. Cont.

NO	Compounds	Molecular Formula	Parts of Plant	References
Cytisine-type alkaloids				
50	(-)-Cytisine	C ₁₁ H ₁₄ N ₂ O	Seeds	[19]
51	N-Methylcytisine	C ₁₂ H ₁₆ N ₂ O	Seeds	[19]
52	(-)-N-Formylcytisine	C ₁₂ H ₁₄ N ₂ O ₂	Seeds	[19]
53	N-Acylcytisine	C ₁₃ H ₁₆ N ₂ O ₂	Seeds	[19]
54	(-)-N-Methylcytisine	C ₁₂ H ₁₆ N ₂ O	Roots	[18]
55	(-)-N-Hexanoylcytisine	C ₁₇ H ₂₄ N ₂ O ₂	Roots	[24]
56	(-)-N-Ethylcytisine	C ₁₃ H ₁₈ N ₂ O	Roots	[24]
57	(-)-N-Propionylcytisine	C ₁₄ H ₁₈ N ₂ O ₂	Roots	[24]
58	Tonkinensine A	C ₂₈ H ₂₆ N ₂ O ₆	Roots	[25]
59	Tonkinensine B	C ₂₈ H ₂₆ N ₂ O ₆	Roots	[25]
Anagyrine-type alkaloids				
60	17-Oxo- α -isosparteine	C ₁₅ H ₂₄ N ₂ O	Leaves	[21]
61	(-)-Anagyrine	C ₁₅ H ₂₀ N ₂ O	Roots	[12]
62	(-)-Thermopsine	C ₁₅ H ₂₀ N ₂ O	Roots	[12]
63	(-)-Baptifoline	C ₁₅ H ₂₀ N ₂ O ₂	Leaves	[21]
64	(-)-Clathrotropine	C ₁₇ H ₂₂ N ₂ O ₄	Roots	[26]
65	Lanatine A	C ₂₂ H ₂₉ N ₃ O ₃	Roots	[26]
Lupine-types and other alkaloids				
66	Lamprolobine	C ₁₅ H ₂₄ N ₂ O ₂	Leaves	[21]
67	Jussiaeiine B	C ₁₆ H ₂₄ N ₂ O ₂	Roots	[26]
68	Jussiaeiine A	C ₁₃ H ₂₀ N ₂ O ₂	Roots	[26]
69	Senepodine H	C ₁₄ H ₂₆ NO ⁺	Roots	[26]
70	Cermizine C	C ₁₁ H ₂₁ N	Roots	[26]
71	Senepodine G	C ₁₁ H ₂₀ N ⁺	Roots	[26]
72	Harmine	C ₁₃ H ₁₂ N ₂ O	Roots	[1]
73	Tonkinensine C	C ₁₆ H ₁₆ N ₂ O ₂	Roots	[1]
74	Perlolyrine	C ₁₆ H ₁₂ N ₂ O ₂	Roots	[1]
75	3-(4-Hydroxyphenyl)-4-(3-methoxy-4-hydroxyphenyl)-3,4-dehydroquinolizidine	C ₂₂ H ₂₅ NO ₃	Roots	[26]
76	1-(6,7-dihydro-5H-pyrrolo[1,2- <i>a</i>]imidazol-3-yl)ethanone	C ₈ H ₁₀ N ₂ O	Roots	[27]
77	Cyclo (Pro-Pro)	C ₁₀ H ₁₄ N ₂ O ₂	Roots	[27]
78	Nicotinic acid	C ₆ H ₅ NO ₂	Roots	[27]
Flavonoids				
79	4',7-Dihydroxyflavone	C ₁₅ H ₁₀ O ₄	Roots	[28]
80	Wogonin	C ₁₆ H ₁₂ O ₅	Roots	[29]
81	Luteolin	C ₁₅ H ₁₀ O ₄	Roots	[29]
82	Luteolin-7-glucoside	C ₂₁ H ₂₀ O ₁₁	Roots	[30]
83	Baicalein 7-O- β -D-glucuronide	C ₂₁ H ₁₈ O ₁₁	Roots	[31]
84	Bayin	C ₂₁ H ₂₀ O ₉	Roots	[15]
85	Swertisin	C ₂₂ H ₂₂ O ₁₀	Roots	[31]
86	Sophoraflavone B	C ₂₁ H ₂₀ O ₉	Roots	[32]
87	Sophoraflavone A	C ₂₇ H ₃₀ O ₁₃	Roots	[32]
Flavonols				
88	Quercetin	C ₁₅ H ₁₀ O ₇	Roots	[33]
89	Morin	C ₁₅ H ₁₀ O ₇	Roots	[31]
90	6,8-Diprenylkaempferol	C ₂₅ H ₂₆ O ₆	Roots	[34]
91	8-C-prenylkaempferol	C ₂₀ H ₁₈ O ₆	Roots	[35]
92	Dehydrolupinifolinol	C ₂₅ H ₂₄ O ₆	Roots	[33]
93	Tonkinensisol	C ₂₅ H ₂₄ O ₆	Roots	[15]
94	Isoquercitrin	C ₂₁ H ₂₀ O ₁₂	Roots	[36]
95	Quercitrin	C ₂₁ H ₂₀ O ₁₁	Roots	[37]
96	Rutin (Quercetin-3-O- β -D-rutinoside)	C ₂₇ H ₃₀ O ₁₆	Roots	[31]
97	Isorhamnetin-3-O- β -D-rutinoside	C ₂₈ H ₃₂ O ₁₆	Roots	[31]

Table 1. Cont.

NO	Compounds	Molecular Formula	Parts of Plant	References
Isoflavones and Dihydroisoflavones				
98	8,4'-Dihydroxy-7-methoxyisoflavone	C ₁₆ H ₁₂ O ₅	Roots	[38]
99	5,7,2',4'-Tetrahydroxyisoflavone	C ₁₅ H ₁₀ O ₆	Roots	[38]
100	Calycosin	C ₁₆ H ₁₂ O ₅	Roots	[38]
101	7,3'-Dihydroxy-5'-methoxyisoflavone	C ₁₆ H ₁₂ O ₅	Roots	[38]
102	7,4'-Dihydroxy-3'-methoxyisoflavone	C ₁₆ H ₁₂ O ₅	Roots	[38]
103	Daidzein (7,4'-Dihydroxyisoflavone)	C ₁₅ H ₁₀ O ₄	Roots	[38]
104	7,3'-Dihydroxy-8,4'-dimethoxyisoflavone	C ₁₇ H ₁₄ O ₆	Roots	[38]
105	7,8-Dihydroxy-4'-methoxyisoflavone	C ₁₆ H ₁₂ O ₅	Roots	[38]
106	7,3',4'-Trihydroxyisoflavone	C ₁₅ H ₁₀ O ₅	Roots	[38]
107	Formononetin	C ₁₆ H ₁₂ O ₄	Roots	[39]
108	Genistein	C ₁₅ H ₁₀ O ₅	Roots	[39]
109	Wighteone	C ₂₀ H ₁₈ O ₅	Roots	[40]
110	8-Methylretusin	C ₁₇ H ₁₄ O ₅	Roots	[41]
111	7-Methoxyebenosis	C ₂₂ H ₂₂ O ₄	Roots	[42]
112	Tectorigenin	C ₁₆ H ₁₂ O ₆	Roots	[43]
113	Butesuperin A	C ₂₆ H ₂₂ O ₈	Roots	[44]
114	Butesuperin B -7'-O-β-glucopyranoside	C ₃₃ H ₃₄ O ₁₄	Roots	[44]
115	Genistin	C ₂₁ H ₂₀ O ₁₀	Roots	[33]
116	Ononin (Formononetin-7-O-β-D-glucoside)	C ₂₂ H ₂₂ O ₉	Roots	[33]
117	Daidzein-4'-glucoside-rhamnoside	C ₂₇ H ₃₀ O ₁₃	Roots	[37]
118	Sophorabioside	C ₂₇ H ₃₀ O ₁₄	Roots	[37]
Dihydroflavones				
119	6,8-Diprenyl-7,4'-Dihydroxyflavanone	C ₂₅ H ₂₈ O ₄	Roots	[45]
120	Sophoranone	C ₃₀ H ₃₆ O ₄	Roots	[45]
121	Glabrol	C ₂₅ H ₂₈ O ₄	Roots	[45]
122	6,8-Diprenyl-7,2',4'-trihydroxyflavanone	C ₂₅ H ₂₈ O ₅	Roots	[45]
123	Lespeflorin B ₄	C ₃₀ H ₃₆ O ₆	Roots	[33]
124	(2S)-7,4'-Dihydroxy-5'-aldehyde-8,3'-(3''-methylbut-2''-enyl) flavanone	C ₂₆ H ₂₈ O ₅	Roots	[34]
125	(2S)-7,2',4'-Trihydroxy-8,3',5'-(3''-methyl-but-2''-enyl) flavanone	C ₃₀ H ₃₆ O ₅	Roots	[34]
126	Tonkinochromane J	C ₂₅ H ₂₈ O ₅	Roots	[46]
127	Shandougenine C	C ₃₀ H ₃₆ O ₅	Roots	[40]
128	Shandougenine D	C ₂₅ H ₂₈ O ₅	Roots	[40]
129	Sophoratonin F	C ₃₅ H ₄₄ O ₄	Roots	[42]
130	Lonchocarpol A	C ₂₅ H ₂₈ O ₅	Roots	[42]
131	2'-Hydroxyglabrol	C ₂₅ H ₂₈ O ₅	Roots	[47]
132	8,5'-Diprenyl-7,2',4'-trihydroxyflavanone	C ₂₅ H ₂₈ O ₅	Roots	[45]
133	Sophoratonin A	C ₂₇ H ₂₈ O ₄	Roots	[42]
134	Sophoratonin B	C ₃₀ H ₃₂ O ₄	Roots	[42]
135	Tonkinochromane I	C ₃₀ H ₃₆ O ₅	Roots	[35]
136	Tonkinochromane G	C ₃₀ H ₃₆ O ₅	Roots	[34]
137	Sophoratonin C	C ₃₀ H ₃₀ O ₄	Roots	[42]
138	Sophoratonin D	C ₃₀ H ₃₆ O ₄	Roots	[42]
139	Flemichin D	C ₂₅ H ₂₆ O ₅	Roots	[45]
140	5-Dehydroxylupinifolin	C ₂₅ H ₂₆ O ₄	Roots	[34]
141	Lupinifolin	C ₂₅ H ₂₆ O ₅	Roots	[40]
142	2-(2',4'-Dihydroxyphenyl)-8,8-dimethyl-1'-(3-methyl-2-butenyl)-8H-pyrano[2,3-d] chroman-4-one	C ₂₅ H ₂₆ O ₅	Roots	[48]
143	Tonkinochromane A	C ₃₀ H ₃₆ O ₄	Roots	[45]
144	Sophoranochromene	C ₃₀ H ₃₄ O ₄	Roots	[33]
145	2-[[2-(1-Hydroxy-1-methylethyl)-7-(3-methyl-2-butenyl)-2',3-dihydrobenzofuran]-5-yl]-7-hydroxy-8-(3-methyl-2-butenyl)-chroman-4-one	C ₃₀ H ₃₆ O ₅	Roots	[49]

Table 1. Cont.

NO	Compounds	Molecular Formula	Parts of Plant	References
Dihydroflavones				
146	Sophoratonin E	C ₃₀ H ₃₂ O ₄	Roots	[42]
147	Tonkinochromane D	C ₃₀ H ₃₈ O ₅	Roots	[50]
148	Tonkinochromane E	C ₃₂ H ₄₂ O ₅	Roots	[50]
149	2-[[2'-(1-Hydroxy-1-methylethyl)-7'-(3-methyl-2-butenyl)-2',3'-dihydrobenzofuran]-5'-yl]-7-hydroxy-8-(3-methyl-2-butenyl)chroman-4-one	C ₃₀ H ₃₆ O ₅	Whole	[51]
150	Euchrenone A ₂	C ₂₅ H ₂₆ O ₅	Roots	[33]
151	Sophoratonin G	C ₂₇ H ₂₈ O ₄	Roots	[42]
152	Tonkinochromane K	C ₃₀ H ₃₆ O ₆	Roots	[46]
153	2-[[3'-Hydroxy-2',2'-dimethyl-8'-(3-methyl-2-butenyl)]chroman-6'-yl]-7-hydroxy-8-(3-methyl-2-butenyl)chroman-4-one	C ₃₀ H ₃₆ O ₅	whole	[51]
154	2-[[3-Hydroxy-2',2'-dimethyl-8-(3-methyl-2-butenyl)]chroman-6-yl]-7-hydroxy-8-(3-methyl-2-butenyl)chroman-4-one	C ₃₁ H ₃₈ O ₄	Roots	[49]
155	Tonkinochromane H	C ₃₀ H ₃₄ O ₅	Roots	[52]
156	Tonkinochromane B	C ₃₀ H ₃₆ O ₄	Roots	[53]
157	Kushenol E	C ₂₅ H ₂₈ O ₆	Roots	[46]
158	Naringenin 7-O-neo-hesperidoside	C ₂₇ H ₃₂ O ₁₄	Roots	[31]
Chalcones and Dihydrochalcones				
159	Isoliquiritigenin	C ₁₅ H ₁₂ O ₄	Roots	[47]
160	Sophoradin	C ₃₀ H ₃₆ O ₄	Roots	[34]
161	Xanthohumol	C ₂₁ H ₂₂ O ₅	Roots	[54]
162	7,9,2,4-Tetrahydroxy-8-isopentenyl-5-methoxychalcone	C ₂₁ H ₂₂ O ₆	Roots	[54]
163	Tonkinochromane C	C ₂₈ H ₃₀ O ₄	Roots	[53]
164	Tonkinochromane F	C ₃₂ H ₄₂ O ₅	Roots	[50]
165	Kuraridine	C ₂₆ H ₃₀ O ₆	Roots	[54]
166	Sophoradichromene	C ₃₀ H ₃₄ O ₄	Roots	[42]
167	Tonkinochromane L	C ₂₁ H ₂₄ O ₄	Roots	[46]
Pterostanes				
168	(-)-Maackiain	C ₁₆ H ₁₂ O ₅	Roots	[33]
169	Pisatin	C ₁₇ H ₁₄ O ₆	Roots	[39]
170	Maackiain-3-O-glucoside 6''-acetate	C ₂₄ H ₂₄ O ₁₁	Roots	[47]
171	(-)-Maackiain 3-sulfate	C ₁₆ H ₁₁ O ₈ S	Roots	[55]
172	6aR,11aR-1-hydroxy-4-isoprenyl-maackiain	C ₂₁ H ₂₀ O ₆	Roots	[48]
173	(6aR,11aR) - 2-hydroxy-3-methoxy-1-isopentenyl-maackiain	C ₂₂ H ₂₂ O ₆	Roots	[47]
174	Sophotokin	C ₂₁ H ₂₀ O ₆	Roots	[34]
175	(-)-Pterocarpin	C ₁₇ H ₁₄ O ₅	Seeds	[56]
176	Medicarpin	C ₁₆ H ₁₄ O ₄	Roots	[39]
177	(6aR, 11aR)-3-O-β-D-Glucopyranosylmedicarpin	C ₂₂ H ₂₄ O ₉	Roots	[24]
178	Medicarpin-3-O-glucoside 6''-acetate	C ₂₄ H ₂₆ O ₁₀	Roots	[47]
179	Demethylmedicarpin	C ₁₅ H ₁₂ O ₄	Roots	[40]
180	Homopterocarpin	C ₁₇ H ₁₆ O ₄	Roots	[42]
181	Dehydromaackiain	C ₁₆ H ₁₀ O ₅	Roots	[42]
182	Flemichapparin B	C ₁₇ H ₁₂ O ₅	Roots	[42]
183	Maackiapterocarpin B	C ₂₁ H ₁₈ O ₆	Roots	[57]
184	3-Methylmaackiapterocarpin B	C ₂₂ H ₂₀ O ₆	Roots	[47]
185	Erybraedin D	C ₂₅ H ₂₆ O ₄	Roots	[42]
186	Maackiapterocarpin A	C ₂₁ H ₂₀ O ₆	Roots	[42]
187	Medicagol	C ₁₆ H ₈ O ₆	Seeds	[56]
188	Sophtonseedlin B	C ₂₈ H ₂₈ O ₁₃	Seeds	[56]
189	Sophoratonkin	C ₂₆ H ₂₆ O ₁₁	Roots	[28]
190	(-)-Trifolirhizin	C ₂₂ H ₂₂ O ₁₀	Seeds	[56]
191	(-)-Trifolirhizin-6''-monoacetate	C ₂₄ H ₂₄ O ₁₁	Seeds	[56]

Table 1. Cont.

NO	Compounds	Molecular Formula	Parts of Plant	References
Flavanols				
192	7,2'-Dihydroxy-4'-methoxy-isoflavanol	C ₁₆ H ₁₆ O ₅	Roots	[58]
193	(3 <i>S</i> ,4 <i>R</i>)-4-hydroxy-7,4'-dimethoxyisoflavan 3'-O-β-D-glucopyranoside	C ₂₃ H ₂₈ O ₁₀	Roots	[24]
Triterpenoids and Triterpenoid saponins				
194	Subprogenin A	C ₃₀ H ₄₈ O ₄	Roots	[59]
195	Subprogenin B	C ₃₀ H ₄₈ O ₅	Roots	[59]
196	Subprogenin C	C ₃₀ H ₄₆ O ₄	Roots	[59]
197	Subprogenin C methylester	C ₃₁ H ₄₈ O ₄	Roots	[59]
198	Subprogenin D	C ₃₀ H ₄₆ O ₄	Roots	[59]
199	Subprogenin D methylester	C ₃₁ H ₄₈ O ₄	Roots	[59]
200	Abrisapogenol H	C ₃₀ H ₄₈ O ₃	Roots	[59]
201	Wistariasapogenol A	C ₃₀ H ₄₈ O ₄	Roots	[59]
202	Melilotigenin	C ₃₀ H ₄₆ O ₅	Roots	[59]
203	Abrisapogenol I	C ₃₀ H ₄₆ O ₅	Roots	[59]
204	Sophoradiol	C ₃₀ H ₅₀ O ₂	Roots	[59]
205	Cantoniensistiol	C ₃₀ H ₅₀ O ₃	Roots	[59]
206	Soyasapogenol B	C ₃₀ H ₅₀ O ₃	Roots	[59]
207	Soyasapogenol A	C ₃₀ H ₅₀ O ₄	Roots	[59]
208	Abrisapogenol C	C ₃₀ H ₅₀ O ₄	Roots	[59]
209	Abrisapogenol D	C ₃₀ H ₅₀ O ₃	Roots	[59]
210	Abrisapogenol E	C ₃₀ H ₅₀ O ₄	Roots	[59]
211	Kudzusapogenol A	C ₃₀ H ₅₀ O ₅	Roots	[59]
212	Abrisapogenol A	C ₃₀ H ₅₀ O ₃	Roots	[59]
213	Lupeol	C ₃₀ H ₅₀ O	Roots	[60]
214	Stigmasterol	C ₂₉ H ₄₈ O	Roots	[60]
215	β-Sitosterol	C ₂₉ H ₅₀ O	Roots	[60]
216	Daucosterol	C ₃₅ H ₆₀ O ₆	Roots	[60]
217	Subproside I	C ₄₈ H ₇₈ O ₁₉	Roots	[61]
218	Subproside I methylester	C ₄₉ H ₈₀ O ₁₉	Roots	[61]
219	Subproside II	C ₄₇ H ₇₆ O ₁₉	Roots	[61]
220	Subproside II methylester	C ₄₈ H ₇₈ O ₁₉	Roots	[61]
221	Soyasaponin A ₃ methylester	C ₄₉ H ₈₀ O ₁₉	Roots	[62]
222	Kuzusapogenol A methylester	C ₄₉ H ₈₀ O ₂₀	Roots	[62]
223	Soyasaponin I methylester	C ₄₉ H ₈₀ O ₁₈	Roots	[62]
224	Kaikasaponin III methylester	C ₄₉ H ₈₀ O ₁₇	Roots	[62]
225	Soyasaponin II methylester	C ₄₈ H ₇₈ O ₁₇	Roots	[62]
226	Kaikasapomn I methylester	C ₄₉ H ₈₀ O ₁₇	Roots	[62]
227	Kudzusaponin A ₃	C ₄₇ H ₇₆ O ₁₉	Roots	[61]
228	Soyasaponin II	C ₄₇ H ₇₆ O ₁₇	Roots	[61]
229	Dehydrosoyasaponin I	C ₄₈ H ₇₆ O ₁₈	Roots	[61]
230	Subproside VII	C ₅₉ H ₉₆ O ₂₇	Roots	[63]
231	Subproside VII methylester	C ₆₀ H ₉₈ O ₂₇	Roots	[63]
232	Subproside IV	C ₅₄ H ₈₈ O ₂₃	Roots	[63]
233	Subproside IV methylester	C ₅₅ H ₉₀ O ₂₃	Roots	[63]
234	Subproside V	C ₅₄ H ₈₈ O ₂₄	Roots	[63]
235	Subproside V methylester	C ₅₅ H ₉₀ O ₂₄	Roots	[63]
236	Subproside III	C ₅₄ H ₈₆ O ₂₄	Roots	[61]
237	Subproside III methylester	C ₅₅ H ₈₈ O ₂₄	Roots	[61]
238	Subproside VI	C ₅₄ H ₈₈ O ₂₄	Roots	[63]
239	Subproside VI methylester	C ₅₅ H ₉₀ O ₂₄	Roots	[63]
Other compounds				
240	Tyrosol	C ₈ H ₁₀ O ₂	Roots	[64]
241	4-(3-Hydroxypropyl) phenol	C ₉ H ₁₂ O ₂	Roots	[64]
242	Vanillin alcohol	C ₈ H ₁₀ O ₃	Roots	[64]
243	(±)-4-(2-Hydroxypropyl) phenol	C ₉ H ₁₂ O ₂	Roots	[64]
244	3,4,5-Trihydroxybenzoic acid	C ₇ H ₆ O ₅	Roots	[31]

Table 1. Cont.

NO	Compounds	Molecular Formula	Parts of Plant	References
Other compounds				
245	3,4-Dihydroxybenzoic acid	C ₇ H ₆ O ₄	Roots	[31]
246	4-Hydroxy-3-methoxybenzoic acid	C ₈ H ₈ O ₄	Roots	[31]
247	<i>p</i> -Hydroxybenzoic acid	C ₇ H ₆ O ₃	Roots	[31]
248	Venillic acid	C ₈ H ₈ O ₄	Roots	[41]
249	<i>p</i> -Methoxybenzoic acid	C ₈ H ₈ O ₃	Roots	[27]
250	Salicylic acid	C ₇ H ₆ O ₃	Roots	[43]
251	Benzamide	C ₇ H ₇ NO	Roots	[64]
252	4-Methoxybenzamide	C ₈ H ₉ NO ₂	Roots	[64]
253	Docosyl caffeate	C ₃₁ H ₅₂ O ₄	Roots	[4]
254	Maltol	C ₆ H ₆ O ₃	Roots	[41]
255	(±)-3-(<i>p</i> -Methoxyphenyl)-1,2-propanediol	C ₉ H ₁₂ O ₄	Roots	[64]
256	3,4-Dimethoxybenzeneacrylic acid methyl ester	C ₁₂ H ₁₄ O ₄	Roots	[39]
257	Sophoratonin H	C ₂₂ H ₂₆ O ₅	Roots	[42]
258	Piscidic acid monoethyl ester	C ₁₃ H ₁₆ O ₇	Roots	[41]
259	2',4',7-trihydroxy-6,8-bis(3-methyl-2-butenyl) flavanone	C ₂₅ H ₂₈ O ₅	Roots	[40]
260	2-(2',4'-dihydroxyphenyl)-5,6-methylenedioxybenzofuran	C ₁₅ H ₁₀ O ₅	Roots	[56]
261	bolusanthin IV	C ₁₅ H ₁₂ O ₄	Roots	[40]
262	7,2'-Dihydroxy-4',5'-methylenedioxyisoflavan	C ₁₆ H ₁₄ O ₅	Roots	[40]
263	Shandougenine A	C ₃₀ H ₁₈ O ₁₀	Roots	[40]
264	Shandougenine B	C ₃₀ H ₁₈ O ₁₀	Roots	[40]
265	(-)-Syringaresinol-4,4'-di-O-β-D-glucopyranoside	C ₃₄ H ₄₆ O ₁₈	Roots	[27]
266	(-)-Syringaresinol-4-O-β-D-glucopyranoside	C ₂₈ H ₃₆ O ₁₃	Roots	[27]
267	(-)-Pinoresinol-4,4'-di-O-β-D-glucopyranoside	C ₃₂ H ₄₂ O ₁₆	Roots	[27]
268	Pinoresinol	C ₂₀ H ₂₂ O ₆	Roots	[28]
269	Syringaresinol	C ₂₂ H ₂₆ O ₈	Roots	[28]
270	Medioresinol	C ₂₁ H ₂₄ O ₇	Roots	[28]
271	Coniferin	C ₁₆ H ₂₂ O ₈	Roots	[27]
272	4-Hydroxymethyl-2,6-dimethoxyphenol-1-O-β-D-glucopyranoside	C ₁₅ H ₂₂ O ₉	Roots	[27]
273	Syringin	C ₁₇ H ₂₄ O ₉	Roots	[29]
274	Sophtonseedlin A	C ₂₃ H ₁₄ O ₉	Roots	[56]
275	(6S,9R)-Roseoside	C ₁₉ H ₃₀ O ₈	Roots	[27]
276	(-)-Secoisolariciresinol-4-O-β-D-glucopyranoside	C ₂₅ H ₃₃ NO ₉	Roots	[27]
Compounds produced by endophytic fungi				
277	2-Methoxy-6-methyl-1,4-benzoquinone	C ₈ H ₈ O ₃	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]
278	1-Methyl emodin	C ₁₆ H ₁₂ O ₅	Endophytic Fungus <i>Penicillium macrosclerotiorum</i>	[66]
279	Isorhodoptilometrin	C ₁₇ H ₁₄ O ₆	Endophytic Fungus <i>Penicillium macrosclerotiorum</i>	[66]
280	(-)-5-Carboxymellein	C ₁₁ H ₁₀ O ₅	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]
281	(-)-5-Methylmellein	C ₁₁ H ₁₂ O ₃	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[67]
282	Xylariphilone	C ₁₁ H ₁₆ O ₄	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]

Table 1. Cont.

NO	Compounds	Molecular Formula	Parts of Plant	References
Compounds produced by endophytic fungi				
283	Xylarphthalide A	C ₁₁ H ₁₀ O ₆	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]
284	2-Anhydromevalonic acid	C ₆ H ₁₀ O ₃	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]
285	(2 <i>S</i> ,5 <i>R</i>)-2-Ethyl-5-methylhexanedioic acid	C ₉ H ₁₆ O ₄	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]
286	6-Heptanoyl-4-methoxy-2H-pyran-2-one	C ₁₃ H ₁₈ O ₄	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]
287	Xylareremophil	C ₁₅ H ₁₈ O ₃	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[68]
288	1 α ,10 α -Epoxy-13-hydroxyremophil-7(11)-en-12,8- β -olide	C ₁₅ H ₂₀ O ₄	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[68]
289	1 α ,10 α -Epoxy-3 α -hydroxyremophil-7(11)-en-12,8- β -olide	C ₁₅ H ₂₀ O ₅	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[68]
290	Mairetolide B	C ₁₅ H ₂₀ O ₄	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[68]
291	Mairetolide G	C ₁₅ H ₂₂ O ₅	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[68]
292	1 β ,10 α ,13-Trihydroxyremophil-7(11)-en-12,8-olide	C ₁₆ H ₂₄ O ₄	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[65]
293	(-)-3-Carboxypropyl-7-hydroxyphthalide	C ₁₂ H ₁₂ O ₅	Endophytic fungus <i>Penicillium</i> <i>vulpinum</i>	[69]
294	(-)-3-Carboxypropyl-7-hydroxyphthalide methyl ester	C ₁₃ H ₁₄ O ₅	Endophytic fungus <i>Penicillium</i> <i>vulpinum</i>	[69]
295	Sulochrin	C ₁₇ H ₁₆ O ₇	Endophytic fungus <i>Penicillium</i> <i>macrosclerotiorum</i>	[66]
296	Monoacetylasteric acid	C ₁₈ H ₁₆ O ₉	Endophytic fungus <i>Penicillium</i> <i>macrosclerotiorum</i>	[66]
297	Methyl dichloroasterrate	C ₁₈ H ₁₆ Cl ₂ O ₈	Endophytic Fungus <i>Penicillium</i> <i>macrosclerotiorum</i>	[66]
298	Penicillither	C ₁₈ H ₁₇ ClO ₈	Endophytic fungus <i>Penicillium</i> <i>macrosclerotiorum</i>	[66]
299	Methyl asterrate	C ₁₈ H ₁₈ O ₈	Endophytic fungus <i>Penicillium</i> <i>macrosclerotiorum</i>	[66]
300	Asterric acid	C ₁₇ H ₁₆ O ₈	Endophytic fungus <i>Penicillium</i> <i>macrosclerotiorum</i>	[66]

Table 1. Cont.

NO	Compounds	Molecular Formula	Parts of Plant	References
Compounds produced by endophytic fungi				
301	Xylapeptide A	C ₃₀ H ₄₅ N ₅ O ₅	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[70]
302	Xylapeptide B	C ₂₉ H ₄₃ N ₅ O ₅	Endophytic Fungus <i>Xylaria</i> sp. GDG-102	[70]
303	21-Acetoxyctochalasin J ₂	C ₃₀ H ₃₇ NO ₄	Endophytic fungus <i>Diaporthe</i> sp. GDG-118	[71]
304	21-Acetoxyctochalasin J ₃	C ₃₀ H ₃₉ NO ₃	Endophytic fungus <i>Diaporthe</i> sp. GDG-118	[71]
305	Cytochalasin J ₃	C ₃₂ H ₄₁ NO ₄	Endophytic fungus <i>Diaporthe</i> sp. GDG-118	[71]
306	Cytochalasin H	C ₃₀ H ₃₉ NO ₅	Endophytic fungus <i>Diaporthe</i> sp. GDG-118	[71]
307	7-Acetoxyctochalasin H	C ₃₂ H ₄₁ NO ₆	Endophytic fungus <i>Diaporthe</i> sp. GDG-118	[71]
308	Cytochalasin J	C ₂₈ H ₃₇ NO ₄	Endophytic fungus <i>Diaporthe</i> sp. GDG-118	[71]
309	Geomycin A	C ₃₅ H ₃₂ O ₁₅	Endophytic fungus <i>Penicillium macrosclerotiorum</i>	[66]
310	Cytochalasin E	C ₂₈ H ₃₃ NO ₇	Endophytic fungus <i>Diaporthe</i> sp. GDG-118	[71]
311	Cytochalasin K	C ₂₈ H ₃₃ NO ₇	Endophytic fungus <i>Xylaria</i> sp. GDG-102	[65]
312	Diaporthein B	C ₂₀ H ₂₈ O ₆	Endophytic fungus <i>Xylaria</i> sp. GDGJ-368	[72]
313	Piliformic	C ₁₁ H ₁₈ O ₄	Endophytic fungus <i>Xylaria</i> sp. GDGJ-368	[72]
314	Cytochalasin C	C ₃₀ H ₃₇ NO ₆	Endophytic fungus <i>Xylaria</i> sp. GDGJ-368	[72]
315	Cytochalasin D	C ₃₀ H ₃₇ NO ₆	Endophytic fungus <i>Xylaria</i> sp. GDGJ-368	[72]
316	(22E)-ergosta-6,22-diene-3β,5β,8α-triol	C ₂₈ H ₄₆ O ₃	Endophytic fungus <i>Xylaria</i> sp. GDGJ-368	[72]




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Cont.




Figure 1. Structures of compounds 1–316 from *S. tonkinensis*.

2.1. Alkaloids

The alkaloids isolated in *S. tonkinensis* were mainly quinolizidine-type alkaloids [73]. To date, 78 alkaloids have been identified and isolated, of which 49 (1–49) are matrine type alkaloids. Sophtonseedline A (46) was isolated from the seeds of *S. tonkinensis*, which featured an unprecedented 5/6/6/6 tetracyclic skeleton [19]. Meanwhile, tonkinensines

A (58) and B (59) with the rare multi group bridging structures were isolated from *S. tonkinensis* also [25].

2.2. Flavonoids

Flavonoids generically referred to the compounds with C6-C3-C6 structure skeleton. The flavonoids were rich in *S. tonkinensis*, and more than 115 flavonoids have been reported as far as we know. Their structural types can be classified as flavonoids (79–87), flavonols (88–97), isoflavones and dihydroisoflavones (98–118), dihydroflavones (119–158), chalcones and dihydrochalcones (159–167), pterostanes (168–191), and flavanols (192–193). Interestingly, tonkinochromanes A (143) and B (156) may ring-fused in the isoprenyl substituents [53]. Meanwhile, sophoraflavones A (87) and B (86) were the rare 5-deoxyflavonoids from the roots of *S. tonkinensis* [32]. Among the eighteen flavonoids identified using UPLC-ESI-LTQ/MS methods, formononetin (107), quercetin (88), rutin (96), isoquercitrin (94), and quercitrin (95) were suggested as the major quality markers of *S. tonkinensis* roots [37].

2.3. Triterpenoids and Triterpenoid Saponins

As far as we know, more than 46 (194–239) triterpenoids and triterpenoid saponins have been isolated from *S. tonkinensis*. Isolated triterpenoids are mainly of the oleanane type with carbonyl substitution at position C-22 [30,74]. Compared with flavonoids and alkaloids, the triterpenoids and triterpenoid saponins of *S. tonkinensis* were rarely reported [59,61,62].

2.4. Other Compounds

In addition to alkaloids, flavonoids, and triterpenoids, a total of 37 (240–276) phenolic acids, sterols, and other compounds were reported from *S. tonkinensis*. Two new 2-arylbenzofuran dimers, shandougenines A (263) and B (264), were isolated from the roots of *S. tonkinensis*. It is noteworthy that shandougenine A (263) has the unique dimeric 2-Arylbenzofuran with a C-3\C-5 bond, and shandougenine B (264) was the natural dimeric 2-arylbenzofuran with a novel C-3/C-3 bond [40]. Meanwhile, a new propenyl phenylacetone was also isolated from *S. tonkinensis* and named sophoratonin H (257) [42].

2.5. Compounds Produced by Endophytic Fungi

The endophytic fungus *Xylaria* sp.GDG-102, *Penicillium macrosclerotiorum*, *Penicillium vulpinum*, *Diaporthe* sp.GDG-118, and *Xylaria* sp. GDGJ-368 [65,66,69,71] were isolated from *S. tonkinensis*, and some compounds produced by these endophytic fungi were interesting. More than 40 (277–316) compounds have been isolated from its endophytic fungi. Xylapeptide A (301) identified from the associated fungus *Xylaria* sp. GDG-102 was the first example of cyclopentapeptide with an L-Pip of terrestrial origin [70].

3. Pharmacological Activities

3.1. Anti-Inflammatory Effect

Reported studies have shown the anti-inflammatory activities of *S. tonkinensis* (Table 2) [45,75]. Some novel compounds, including 12,13-dehydrosophoridine (16) from *S. tonkinensis*, showed significant activity against inflammatory cytokines TNF- α and IL-6 on LPS-induced RAW264.7 macrophages [23]. Moreover, 6,8-diprenyl-7,4'-dihydroxyflavanone (DDF) (119) inhibited the production of NO and the expression of TNF- α , IL-1 β , and IL-6 [45]. Meanwhile, the compounds 2'-hydroxyglabrol (131), glabrol (121), maackiain (168), and bolusanthin IV (261) showed strong inhibitory effects on IL-6 [47]. Sophotokin (174) dose-dependently inhibited the lipopolysaccharide (LPS)-stimulated production of NO, TNF- α , PGE₂, and IL-1 β in microglial cells [34]. Moreover, the orally administered roots extract of *S. tonkinensis* attenuated the total leukocytes, eosinophil infiltration, and IL-5 level in BAL fluids [76]. Another study also showed *S. tonkinensis* were able to reduce TNF- α , NO, and IL-6 contents in rat paw edema induced by carrageenan [77].

Table 2. The comprehensive list of the pharmacological activities from *S. tonkinensis*.

Detail	Extracts/Compounds	In Vivo/In Vitro	Active Concentration/Dose	References	
Anti-inflammatory activity					
Reduce TNF- α	(-)-Anagyryne (61)	In vitro	50 μ M	[12]	
	Sophocarpine (34)	In vitro	50 μ M	[12]	
	14 β -Hydroxymatrine (28)	In vitro	50 μ M	[12]	
	7 β -Sophoramine (49)	In vitro	50 μ M	[12]	
	Matrine (1)	In vivo	50 μ M	[12]	
	(+)-5 α -Hydroxymatrine (5)	In vivo	50 μ M	[12]	
	12,13-Dehydrosophoridine (16)	In vitro	50 μ M	[23]	
	13 α -Hydroxymatrine (36)	In vitro	50 μ M	[23]	
	13 β -Hydroxymatrine (37)	In vitro	50 μ M	[23]	
	Isosophocarpine (48)	In vitro	50 μ M	[23]	
	Sophoridine (13)	In vitro	50 μ M	[23]	
	Water extract of roots	In vivo	0.3 g/kg	[75]	
	sophoratonkin (189)	In vitro	IC ₅₀ = 33.0 μ M	[28]	
	Maackiain (168)	In vitro	IC ₅₀ = 27.0 μ M	[28]	
	Sophoranone (120)	In vitro	IC ₅₀ = 28.1 μ M	[28]	
Inhibit the production of NO	Sophoranochromene (144)	In vitro	IC ₅₀ = 13.6 μ M	[28]	
	Tonkinochromane A (143)	In vitro	20 μ M	[45]	
	Flemichin D (139)	In vitro	20 μ M	[45]	
	6,8-Diprenyl-7,4'-dihydroxyflavanone (119)	In vitro	IC ₅₀ = 12.21 μ M	[45]	
	Water extract of roots	In vivo	100 mg/kg	[13]	
	Non-alkaloid extracts of roots	In vivo	400 mg/kg	[13]	
	2'-Hydroxyglabrol (131)	In vitro	IC ₅₀ = 1.62 μ M	[47]	
	Glabrol (121)	In vitro	IC ₅₀ = 0.73 μ M	[47]	
	Maackiain (168)	In vitro	IC ₅₀ = 3.01 μ M	[47]	
	Bolusanthin IV (261)	In vitro	IC ₅₀ = 4.02 μ M	[47]	
	Ethanol extract of roots	In vivo	100 mg/kg	[7]	
	(-)-Anagyryne (61)	In vitro	50 μ M	[12]	
	Sophocarpine (34)	In vitro	50 μ M	[12]	
	14 β -Hydroxymatrine (28)	In vitro	50 μ M	[12]	
	Reduce IL-6	7 β -Sophoramine (49)	In vitro	50 μ M	[12]
Matrine (1)		In vitro	50 μ M	[12]	
(+)-5 α -Hydroxyoxymatrine (3)		In vivo	50 μ M	[12]	
(+)-5 α -Hydroxymatrine (5)		In vivo	50 μ M	[12]	
12,13-Dehydrosophoridine (16)		In vitro	50 μ M	[23]	
13 α -Hydroxymatrine (36)		In vitro	50 μ M	[23]	
13 β -Hydroxymatrine (37)		In vitro	50 μ M	[23]	
Isosophocarpine (48)		In vitro	50 μ M	[23]	
Sophoridine (13)		In vitro	50 μ M	[23]	
Water extract of roots		In vivo	0.3 g/kg	[75]	
Reduce IL-5		50% (v/v) ethanol-water mixture	In vivo	100 mg/kg	[76]
Reduce IL-10		Ethanol extract of roots	In vivo	100 mg/kg	[7]
Reduce IL-1 β		Water extract of roots	In vivo	0.3 g/kg	[75]
Reduced the hyperplasia of goblet cell		50% (v/v) ethanol-water mixture	In vivo	10 mg/kg	[76]
Inhibit xylene induced auricle swelling in mice		Oxymatrine (4)	In vivo	40 mg/kg	[78]
	(-)-Cytisine (50)	In vivo	40 mg/kg	[78]	
	<i>S. tonkinensis</i> particles	In vivo	1.75 g/kg	[79]	
Inhibit pain induced by acetic acid stimulation of the celiac mucosa	Matrine (1)	In vivo	40 mg/kg	[78]	
	Sophoridine (13)	In vivo	30 mg/kg	[78]	
	Sophocarpine (34)	In vivo	40 mg/kg	[78]	
	<i>S. tonkinensis</i> particles	In vivo	3.5 g/kg	[79]	
	Water extract of roots	In vivo	0.35–1.12 g/kg	[80]	
Inhibit croton oil induced ear swelling in mice	Ethanol extract of roots	In vivo	0.35–1.12 g/kg	[80]	
	Water extract of roots	In vivo	0.39 g/kg	[81]	
	Anti-tumor activity				
Inhibit A549	(-)- <i>N</i> -hexanoylcytisine (55)	In vitro	IC ₅₀ = 31.64 μ M	[24]	
	(-)- <i>N</i> -Formylcytisine (52)	In vitro	IC ₅₀ = 22.05 μ M	[24]	
	(6aR, 11aR)-Maackiain (168)	In vitro	IC ₅₀ = 24.58 μ M	[24]	
	Water extracts of roots	In vitro	6.5 μ g/ μ L	[82]	
	1-(6,7-Dihydro-5H-pyrrolo [1,2- <i>a</i>]imidazol-3-yl) ethenone (76)	In vitro	IC ₅₀ = 23.05 \pm 0.46 μ M	[27]	

Table 2. Cont.

Detail	Extracts/Compounds	In Vivo/In Vitro	Active Concentration/Dose	References
Anti-tumor activity				
Inhibit HL-60	Tonkinensisol (93)	In vitro	IC ₅₀ = 36.48 µg/mL	[15]
	Sophoranol (5)	In vitro	10.00 µg/mL	[83]
	13,14-Dehydrosophoranol (24)	In vitro	1.00 µg/mL	[83]
	Tonkinensine C (73)	In vitro	IC ₅₀ = 87.4 ± 7.1 µM	[1]
Inhibit HepG2	Perlolyrine (74)	In vitro	IC ₅₀ = 91.8 ± 3.5 µM	[1]
	Harmine (72)	In vitro	IC ₅₀ = 48.9 ± 5.2 µM	[1]
	Alkaloids	In vitro	IC ₅₀ = 9.04 g/L	[84]
	Non-alkaloids extract of roots	In vitro	IC ₅₀ = 0.98 g/L	[84]
	Water extracts of roots	In vitro	6.5 µg/µL	[82]
Inhibit SH-SY5Y	Sophoranone (120)	In vitro	IC ₅₀ = 18.49 µM	[85]
	Matrine (1)	In vitro	IC ₅₀ = 60.81 µM	[85]
	Oxymatrine (4)	In vitro	IC ₅₀ = 42.56 µM	[85]
	(-)-Trifolirhizin (190)	In vitro	IC ₅₀ = 72.11 µM	[85]
Inhibit B16-BL6	(-)-Maackiain (168)	In vitro	IC ₅₀ = 65.62 µM	[85]
	Extract of roots	In vitro	400 µg/mL	[86]
Inhibit CNE-1, CNE-2	Chloroform extract of roots	In vitro	25 µg/mL	[87]
Inhibit U937	Sophoranone (120)	In vitro	IC ₅₀ = 3.8 ± 0.9 µM	[88]
Inhibit HeLa	Tonkinensine B (59)	In vitro	IC ₅₀ = 24.3 ± 0.3 µM	[25]
Inhibit MDA-MB-231	Tonkinensine B (59)	In vitro	IC ₅₀ = 48.9 ± 0.5 µM	[25]
	Water extract of roots	In vitro	6.5 µg/µL	[82]
Inhibit ESC solid tumor cell	Total alkaloids of roots	In vivo	100 mg/kg	[89]
Inhibit H ₂₂ ascites tumor cells	Total alkaloids of roots	In vivo	100 mg/kg	[89]
Inhibit S ₁₈₀ solid tumor cell	Total alkaloids of roots	In vivo	75 mg/kg	[89]
	Sophotokin (174)	In vitro	10 µM	[34]
Inhibit BV2 glioma cell lines	Maackiain (168)	In vitro	10 µM	[34]
	Medicarpin (176)	In vitro	10 µM	[34]
Inhibit Hep3B and KG-1 cells	Water extract of roots	In vitro	6.5 µg/µL	[82]
Decrease the number of cancer nodules in tumor tissue and reduce AFP in serum	Alkaloids extract of roots	In vivo	0.036 g/kg	[90]
Effects on the liver				
Protect HepG2 cell against acetaminophen (APAP)-induced damage	4-Methoxybenzamide (252)	In vitro	10 µmol/L	[64]
	7,3'-Dihydroxy-8,4'-dimethoxyisoflavone (104)	In vitro	10 µmol/L	[64]
	7,4'-Dihydroxy-3'-methoxyisoflavone (102)	In vitro	10 µmol/L	[64]
	(±)-3-(p-Methoxyphenyl)-1,2-propanediol (255)	In vitro	10 µmol/L	[64]
Enhance L-02 hepatocytes	Matrine (1)	In vivo and vitro	10 µM	[91]
	Oxymatrine (4)	In vivo and vitro	10 µM	[91]
Effects on the liver				
Increase SOD and GSH	Non-alkaloids extract of roots	In vivo	400 mg/kg	[13]
	Water extract of roots	In vivo	400 mg/kg	[13]
Increase ALT and AST	Water extract of roots	In vivo	0.59 g/kg	[92]
Increase CPT 1A activity	Water extract of roots	In vivo	25 µg/mL	[91]
Reduce nonesterified fatty acid Induce cellular lipids accumulation in hepatocytes	Matrine (1)	In vivo	10 µM	[91]
	Oxymatrine (4)	In vivo	10 µM	[91]
Reduce immune liver injury	Oxymatrine (4)	In vivo	60 mg/kg	[93]
	Sophocarpine (34)	In vivo	60 mg/kg	[93]
	Oxymatrine (4)	In vivo	120 mg/kg	[94]
Inhibite acetaminophen-induced hepatic oxidative damage in mice	STRP1 (Polysaccharide part)	In vivo	200 mg/kg	[95]
	STRP2 (Polysaccharide part)	In vivo	200 mg/kg	[95]
Alleviate non-alcoholic fatty liver disease of mice	Water extract of roots	In vivo	90 mg/kg	[91]
Inhibit the production of tyrosinase	Formononetin-7-O-β-D-glucoside(116)	In vitro	IC ₅₀ = (7.82 ± 0.28) × 10 ⁻⁴ mol/L	[43]
	Tectorigenin (112)	In vitro	IC ₅₀ = (3.73 ± 0.45) × 10 ⁻⁴ mol/L	[43]
	8-Prenylkaemferol (91)	In vitro	IC ₅₀ = (1.58 ± 0.31) × 10 ⁻⁵ mol/L	[43]

Table 2. Cont.

Detail	Extracts/Compounds	In Vivo/In Vitro	Active Concentration/Dose	References
Effects on the liver				
Reduce AST and ALT	Oxymatrine (4)	In vivo	120 mg/kg	[93]
	Sophocarpine (34)	In vivo	120 mg/kg	[93]
	Water extract of roots	In vivo	0.25 g/kg	[96]
Reduce AST	Non-alkaloid extract of roots	In vivo	100 mg/kg	[13]
	Water extract of roots	In vivo	200 mg/kg	[13]
Reduce ALT	Non-alkaloid extracts of roots	In vivo	400 mg/kg	[13]
	Water extract of roots	In vivo	200 mg/kg	[13]
Anti-viral activity				
Anti-Coxsackie virus B3	(-)-12 β -Hydroxyoxysophocarpine (18)	In vitro	IC ₅₀ = 26.62 μ M	[14]
	(-)-9 α -Hydroxysophocarpine (25)	In vitro	IC ₅₀ = 197.22 μ M	[14]
	(+)-Sophoranol (5)	In vitro	IC ₅₀ = 252.18 μ M	[14]
	(-)-14 β -Hydroxymatrine (28)	In vitro	IC ₅₀ = 184.14 μ M	[14]
	3-(4-Hydroxyphenyl)-4-(3-methoxy-4-hydroxyphenyl)-3,4-dehydroquinolizidine (75)	In vitro	IC ₅₀ = 6.40 μ M	[26]
	Cermizine C (70)	In vitro	IC ₅₀ = 3.25 μ M	[26]
	Jussiaeiine A (68)	In vitro	IC ₅₀ = 4.66 μ M	[26]
	Jussiaeiine B (67)	In vitro	IC ₅₀ = 3.21 μ M	[26]
	(+)-5 α -Hydroxyoxysophocarpine (17)	In vitro	IC ₅₀ = 0.12 μ M	[26]
	(-)-12 β -Hydroxyoxysophocarpine (18)	In vitro	IC ₅₀ = 0.23 μ M	[26]
	(-)-Clathrotropine (64)	In vitro	IC ₅₀ = 1.60 μ M	[26]
	Sophtonseedlin B (188)	In vitro	100 μ g/mL	[56]
	(-)-Trifolirhizin (190)	In vitro	100 μ g/mL	[56]
Anti-tobacco mosaic virus (TMV)	Sophtonseedline B (21)	In vitro	100 μ g/mL	[19]
	Sophtonseedline D (23)	In vitro	100 μ g/mL	[19]
	Sophtonseedline F (8)	In vitro	100 μ g/mL	[19]
	(-)-N-Formylcytisine (52)	In vitro	100 μ g/mL	[19]
	Alkaloid extracts of seeds	In vitro	0.5 mg/mL	[19]
	Methanol extracts of seeds	In vitro	0.5 mg/mL	[19]
	(+)-Oxysophocarpine (20)	In vitro	0.4 μ mol/mL	[20]
	(-)-Sophocarpine (34)	In vitro	0.4 μ mol/mL	[20]
	(+)-Lehmannine (14)	In vitro	0.4 μ mol/mL	[20]
	(-)-13,14-Dehydrosophoridine (16)	In vitro	1.6 μ mol/mL	[20]
Anti-hepatitis B virus (HBV)	(-)-14 β -Hydroxyoxymatrine (6)	In vitro	0.4 μ mol/mL	[18]
	(+)-Sophoranol (5)	In vitro	0.2 μ mol/mL	[18]
	(-)-Cytisine (50)	In vitro	0.2 μ mol/mL	[18]
Anti-mouse hepatitis virus	Methanol extracts of plant	In vitro	EC ₅₀ = 27.5 \pm 1.1 μ g/mL	[97]
Inhibited influenza virus A/Hanfng/359/95	(+)-12 α -Hydroxysophocarpine (15)	In vitro	IC ₅₀ = 84.70 μ M	[14]
	(-)-12 β -Hydroxysophocarpine (19)	In vitro	IC ₅₀ = 242.46 μ M	[14]
	(+)-Sophoramine (49)	In vitro	IC ₅₀ = 63.07 μ M	[14]
Anti-oxidant capacity				
ABTS free radical scavenging ability	Chloroform extract of roots	In vitro	EC ₅₀ = 1.08 mg/mL	[98]
	Ethyl acetate extract of roots	In vitro	EC ₅₀ = 0.55 mg/mL	[98]
	N-butanol extract of roots	In vitro	EC ₅₀ = 1.27 mg/mL	[98]
	Ethanol extract of roots	In vitro	EC ₅₀ = 3.08 mg/mL	[98]
	Shandougenines A (263)	In vitro	IC ₅₀ = 0.532 \pm 0.076 mM	[40]
	Shandougenines B (264)	In vitro	IC ₅₀ = 0.18 \pm 0.032 mM	[40]
	Bolusanthin IV (261)	In vitro	IC ₅₀ = 0.3 \pm 0.025 mM	[40]
	2-(2',4'-Dihydroxyphenyl)-5,6-methylenedioxybenzofuran (260)	In vitro	IC ₅₀ = 0.726 \pm 0.041 mM	[40]
	Shandougenine C (127)	In vitro	IC ₅₀ = 0.382 \pm 0.055 mM	[40]
	Shandougenine D (128)	In vitro	IC ₅₀ = 0.341 \pm 0.058 mM	[40]
	Demethylmedicarpin (179)	In vitro	IC ₅₀ = 0.503 \pm 0.036 mM	[40]
	Ethyl acetate extract of roots	In vitro	0.5 mg/mL	[98]
	Ethanol extract of roots	In vitro	0.5 mg/mL	[98]
Scavenging of DPPH radicals	Chloroform extract of roots	In vitro	0.5 mg/mL	[98]
	N-butanol extract of roots	In vitro	0.5 mg/mL	[98]
	Water extract of aerial parts	In vitro	IC ₅₀ = 0.1434 g/L	[17]
	N-butyl alcohol extract of aerial parts	In vitro	IC ₅₀ = 0.0754 g/L	[17]
	Ethyl acetate extract of aerial parts	In vitro	IC ₅₀ = 0.0693 g/L	[17]
	Dichloromethane of aerial parts	In vitro	IC ₅₀ = 0.0494 g/L	[17]
	Petroleum ether extract of aerial parts	In vitro	IC ₅₀ = 0.1218 g/L	[17]

Table 2. Cont.

Detail	Extracts/Compounds	In Vivo/In Vitro	Active Concentration/Dose	References
Anti-oxidant capacity				
Scavenging of DPPH radicals	Ethyl acetate extract of roots	In vitro	0.5 mg/mL	[98]
	STRP1 (Polysaccharide part)	In vitro	1.0 mg/mL	[95]
	STRP2 (Polysaccharide part)	In vitro	1.0 mg/mL	[95]
	Tonkinensinol (93)	In vitro	IC ₅₀ = 0.616 ± 0.021 mM	[40]
	Bolusanthin IV (261)	In vitro	IC ₅₀ = 0.502 ± 0.101 mM	[40]
	2-(2',4'-Dihydroxyphenyl)-5,6-methylenedioxybenzofuran (260)	In vitro	IC ₅₀ = 0.527 ± 0.054 mM	[40]
	Shandougenines A (263)	In vitro	IC ₅₀ = 1.213 ± 0.101 mM	[40]
	Shandougenines B (264)	In vitro	IC ₅₀ = 0.327 ± 0.022 mM	[40]
	WRSP-A2b (Polysaccharide part)	In vitro	IC ₅₀ = 19.95 ± 0.25 mg/mL	[99]
	WRSP-A3a (Polysaccharide part)	In vitro	IC ₅₀ = 5.99 ± 0.20 mg/mL	[99]
Reducing power	Chloroform extract of roots	In vitro	EC ₅₀ = 0.60 mg/mL	[98]
	Ethyl acetate extract of roots	In vitro	EC ₅₀ = 0.64 mg/mL	[98]
	N-butanol extract of roots	In vitro	EC ₅₀ = 0.51 mg/mL	[98]
	Ethanol extract of roots	In vitro	EC ₅₀ = 0.84 mg/mL	[98]
	Chloroform extract of roots	In vitro	EC ₅₀ = 1.33 mg/mL	[98]
Hydroxyl radical scavenging ability	Ethyl acetate extract of roots	In vitro	EC ₅₀ = 2.80 mg/mL	[98]
	N-butanol extract of roots	In vitro	EC ₅₀ = 5.00 mg/mL	[98]
	WRSP-A2b (Polysaccharide part)	In vitro	IC ₅₀ = 19.78 ± 0.47 mg/mL	[99]
	WRSP-A3a (Polysaccharide part)	In vitro	IC ₅₀ = 8.38 ± 0.18 mg/mL	[99]
Superoxide anion radical scavenging ability	WRSP-A2b (Polysaccharide part)	In vitro	IC ₅₀ = 4.24 ± 0.11 mg/mL	[99]
	WRSP-A3a (Polysaccharide part)	In vitro	IC ₅₀ = 1.94 ± 0.05 mg/mL	[99]
	Toxicity			
Respiratory depression, muscle fibrillation, convulsions, spasms, and death	Hydroalcoholic extract from the roots	Mice (i.g.)	LD ₅₀ = 9.802 ± 2.0067 g/kg	[100]
Convulsions, hair erection, rapid abdominal contraction and excitement, depression, abdominal breathing and eye closure, and death	(-)- Cytisine (50)	Mice (i.g.)	LD ₅₀ = 48.16 mg/kg	[101]
Irritability, hyperactivity, shortness of breath, and convulsions	Water extract of roots	Mice (i.g.)	LD ₅₀ = 17.469 g/kg	[102]
	90% Ethanol extract of roots	Mice (i.g.)	LD ₅₀ = 27.135 g/kg	[102]
	Alkaloids of roots	Mice (i.g.)	LD ₅₀ = 13.399 g/kg	[102]
	Water and 70% Ethanol extract mixture of roots	Mice (i.g.)	MTD = 36 g/kg	[103]
	All-component of of roots	Mice (i.g.)	MTD = 10.68 g/kg	[102]
Slow heartbeat, bent trunk of zebrafish, accelerated movement frequency, and abnormal movement track, Hepato renal, pericardial enlargement, death.	Sophoranone (120)	Zebrafish (p.o.)	LC ₅₀ = 22.45 µmol/L	[104]
To cause hepatomegaly	Sophoranone (120)	Zebrafish (p.o.)	3.86 µmol/L	[104]
The zebrafish liver lost transparency and became dark or brown, and liver blood flow was no longer observable	Dealkalized water extract of roots	Zebrafish (p.o.)	LC ₁₀ = 1009.1 µg/mL	[105]
	Ethanol sedimentation extract of roots	Zebrafish (p.o.)	LC ₁₀ = 4367.6 µg/mL	[105]
	N-Butyl ethanol extract of roots	Zebrafish (p.o.)	MNLC = 700.0 µg/mL	[105]
Slowed heart rate, reduced blood flow, and absence of circulation in the cardiotoxic phenotype, neurotoxic, and presents with behavioral abnormalities, bent trunk.	Sophoranone (120)	Zebrafish (p.o.)	11.59 µmol/L	[104]
Induced pericardial edema and slowed the blood circulation, heart rate lower	Diethyl ether extract of roots	Zebrafish (p.o.)	LC ₁₀ = 93.6 µg/mL	[105]
	N-Butyl ethanol extract of roots	Zebrafish (p.o.)	LC ₁₀ = 538.3 µg/mL	[105]

Table 2. Cont.

Detail	Extracts/Compounds	In Vivo/In Vitro	Active Concentration/Dose	References
Toxicity				
Pericardial edema, a misshaped atrium and ventricle as well as reduced number of endothelial cells and cardiomyocytes	Dichloromethane extract of roots	Zebrafish (p.o.)	MNLC = 450.0 µg/mL	[105]
Delayed yolk sac resorption in the hepatotoxic phenotype and Intestinal dysplasia	Sophoranone (120)	Zebrafish (p.o.)	1.29 µmol/L	[104]
To cause renal and pericardial edema	Sophoranone (120)	Zebrafish (p.o.)	15.57 µmol/L	[104]
Other pharmacological activities				
Inhibit <i>Pseudomonas aeruginosa</i>	2',4',7-Trihydroxy-6,8-bis(3-methyl-2-butenyl) flavanone (259)	In vitro	MIC = 125.0 µg/mL	[16]
	Genistin (115)	In vitro	MIC = 15.6 µg/mL	[16]
	2-Methoxy-6-methyl-1,4-benzoquinone (277)	In vitro	MIC = 3.125 µg/mL	[65]
Inhibit <i>Bacillus megaterium</i>	Xylariphilone (282)	In vitro	MIC = 12.5 µg/mL	[65]
	Xylarphthalide A (283)	In vitro	MIC = 25 µg/mL	[67]
	(-)-5-Carboxymellein (280)	In vitro	MIC = 25 µg/mL	[67]
	(-)-5-Methylmellein (281)	In vitro	MIC = 25 µg/mL	[67]
	Lanatine A (65)	In vitro	MIC = 1.0 g/L	[26]
	Jussiaeiines A (68)	In vitro	MIC = 3.2 g/L	[26]
	Jussiaeiines B (67)	In vitro	MIC = 0.8 g/L	[26]
	(-)-5-Carboxymellein (280)	In vitro	MIC = 25 µg/mL	[67]
Inhibit <i>Escherichia coli</i>	21-Acetoxytyochalasin J ₃ (304)	In vitro	MIC = 12.5 µg/mL	[71]
	2-(2',4'-Dihydroxy)-5,6-dioxomethylbenzofuran (260)	In vitro	MIC = 31.3 µg/mL	[16]
	Xylarphthalide A (283)	In vitro	MIC = 25 µg/mL	[67]
	(-)-5-Methylmellein (281)	In vitro	MIC = 25 µg/mL	[67]
	6-Heptanoyl-4-methoxy-2H-pyran-2-one (286)	In vitro	MIC = 50 µg/mL	[106]
	3-(4-Hydroxyphenyl)-4-(3-methoxy-4-hydroxyphenyl)-3,4-dehydroquinolizidine (75)	In vitro	MIC = 8.0 g/L	[26]
	Cermizines C (70)	In vitro	MIC = 3.5 g/L	[26]
	Jussiaeiines B (67)	In vitro	MIC = 6.0 g/L	[26]
	Cytochalasin K (311)	In vitro	MIC = 12.5 µg/mL	[65]
Inhibit <i>Staphylococcus aureus</i>	6-Heptanoyl-4-methoxy-2H-pyran-2-one (286)	In vitro	MIC = 50 µg/mL	[106]
	(-)-N-methylcytisine (54)	In vitro	MIC = 12.0 g/L	[26]
	Xylarphthalide A (283)	In vitro	MIC = 25 µg/mL	[67]
	(-)-5-Carboxymellein (280)	In vitro	MIC = 25 µg/mL	[67]
	(-)-5-Methylmellein (281)	In vitro	MIC = 12.5 µg/mL	[67]
	Cytochalasin K (311)	In vitro	MIC = 12.5 µg/mL	[65]
	2',4',7-Trihydroxy-6,8-bis(3-methyl-2-butenyl) flavanone (259)	In vitro	MIC = 62.5 µg/mL	[16]
	Ethyl acetate extract of roots	In vitro	MIC = 0.313 mg/mL	[98]
Inhibit <i>Shigella dysenteriae</i>	Xylarphthalide A (283)	In vitro	MIC = 25 µg/mL	[67]
	(-)-5-Methylmellein (281)	In vitro	MIC = 25 µg/mL	[67]
	(-)-3-Carboxypropyl-7-hydroxyphthalide (293)	In vitro	MIC = 12.5 µg/mL	[69]
Inhibit <i>Proteus vulgaris</i>	Xylareremophil (287)	In vitro	MIC = 25 µg/mL	[68]
	Mairetolide G (291)	In vitro	MIC = 25 µg/mL	[68]
	Mairetolide G (291)	In vitro	MIC = 50 µg/mL	[68]
Inhibit <i>Micrococcus luteus</i>	Mairetolide B (290)	In vitro	MIC = 50 µg/mL	[68]
	Xylareremophil (287)	In vitro	MIC = 25 µg/mL	[68]
	Mairetolide B (290)	In vitro	MIC = 100 µg/mL	[68]
Inhibit <i>Micrococcus lysodeikticus</i>	Mairetolide G (291)	In vitro	MIC = 100 µg/mL	[68]
	Xylareremophil (287)	In vitro	MIC = 100 µg/mL	[68]

Table 2. Cont.

Detail	Extracts/Compounds	In Vivo/In Vitro	Active Concentration/Dose	References
Other pharmacological activities				
Inhibit <i>Bacillus subtilis</i>	(-)-5-Carboxymellein (280)	In vitro	MIC = 12.5 µg/mL	[67]
	Mairetolide B (290)	In vitro	MIC = 100 µg/mL	[68]
	Mairetolide G (291)	In vitro	MIC = 100 µg/mL	[68]
	Xylarphthalide A (283)	In vitro	MIC = 25 µg/mL	[67]
	(-)-5-Methylmellein (281)	In vitro	MIC = 12.5 µg/mL	[67]
	Xylapeptide A (301)	In vitro	MIC = 12.5 µg/mL	[70]
Inhibit <i>Bacillus anthracis</i>	(-)-3-Carboxypropyl-7-hydroxyphthalide (293)	In vitro	MIC = 25 µg/mL	[69]
	Xylarremophil (287)	In vitro	MIC = 100 µg/mL	[68]
	(-)-5-Carboxymellein (280)	In vitro	MIC = 25 µg/mL	[67]
Inhibit <i>Alternaria oleracea</i>	21-Acetoxycytochalasin J ₃ (304)	In vitro	MIC = 12.5 µg/mL	[71]
	Cytochalasin E (310)	In vitro	MIC = 3.125 µg/mL	[71]
Inhibit <i>Colletotrichum capsici</i>	Cytochalasin H (306)	In vitro	MIC = 6.25 µg/mL	[71]
	Cytochalasin E (310)	In vitro	MIC = 1.56 µg/mL	[71]
Inhibit <i>Pestalotiopsis theae</i>	Cytochalasin H (306)	In vitro	MIC = 6.25 µg/mL	[71]
	Cytochalasin E (310)	In vitro	MIC = 1.56 µg/mL	[71]
Inhibit <i>Enterobacter aerogenes</i>	Cytochalasin H (306)	In vitro	MIC = 12.5 µg/mL	[71]
	(-)-3-Carboxypropyl-7-hydroxyphthalide methyl ester (294)	In vitro	MIC = 12.5 µg/mL	[69]
Inhibit <i>Colletotrichum gloeosporioides</i>	(-)-3-Carboxypropyl-7-hydroxyphthalide (293)	In vitro	MIC = 12.5 µg/mL	[69]
	Methanol extract of roots	In vitro	EC ₅₀ = 1.214 mg/mL MIC = 2.5 mg/mL	[107]
Inhibit <i>Fusarium solani</i>	Methanol extract of roots	In vitro	EC ₅₀ = 1.169 mg/mL MIC = 2.5 mg/mL	[107]
Inhibit <i>Ceratocystis paradoxa</i>	Cytochalasin H (306)	In vitro	MIC = 25 µg/mL	[71]
Inhibit <i>Bacillus cereus</i>	Xylapeptide A (301)	In vitro	MIC = 12.5 µg/mL	[70]
Moderate activities against <i>Aphis fabae</i>	Sophtonseedline G (9)	In vivo	LC ₅₀ = 38.29 mg/L	[19]
	Matrine (1)	In vivo	LC ₅₀ = 18.63 mg/L	[19]
Decreased fasting blood glucose levels	(-)-N-Formylcytisine (52)	In vivo	LC ₅₀ = 23.74 mg/L	[19]
	Matrine (1)	In vivo	2.5 mg/kg	[108]
alleviate insulin resistance	Ethyl acetate extract of roots	In vivo	60 mg/kg	[33]
	Ethyl acetate extract of roots	In vivo	60 mg/kg	[33]
Inhibit 5-lipoxygenase	Matrine (1)	In vivo	10 mg/kg	[108]
	50 % (v/v) Ethanol–water mixture	In vitro	IC ₅₀ = 1.61 µg/mL	[76]
	Maackiain (168)	In vitro	IC ₅₀ = 7.9 µM	[76]
Inhibit thromboxane synthase	Sophoranone (120)	In vitro	IC ₅₀ = 1.6 µM	[76]
	50 % (v/v) Ethanol–water mixture	In vitro	IC ₅₀ = 5.56 µg/mL	[76]
Inhibit butyrylcholinesterase	Ethanol extract of roots	In vitro	IC ₅₀ = 15.169 µg/mL	[109]

3.2. Anti-Tumor Effect

The anti-tumor effect was one of the most reported activities of *S. tonkinensis* (Table 2). The chloroform extracts of *S. tonkinensis* have been discovered its inhibitory effect on cell viability and clonal growth in a dose-dependent manner [87]. Meanwhile, the extracts of *S. tonkinensis* also have been reported the inhibit ability target the proliferation, adhesion, invasion, and metastasis of mouse melanoma cells [86]. The anticancer activities of compounds have also been reported [38]. The natural compounds from *S. tonkinensis* exhibited inhibitory effects against different tumor cells. The growth-inhibitory and apoptosis-inducing activities of sophoranone (120) for leukemia U937 cells were investigated [88].

3.3. Hepatoprotective

The components of *S. tonkinensis* were reported significant protective effects against immune induced liver injury (Table 2). Previous works suggested that the nonalkaloid constituents of *S. tonkinensis* obviously reduced the alanine aminotransferase (ALT), aspartate aminotransferase (AST) serum, malondialdehyde (MDA), and nitric oxide (NO), as well as increased the superoxide dismutase (SOD) and glutathione (GSH) in mice with immune-induced liver injury [13]. The water extract of *S. tonkinensis* alleviated hepatic inflammation, liver fibrosis, and hepatic lipids accumulation [91]. Compounds matrine (1)

and oxymatrine (**4**) may be the main components contributing to the lipid-lowering activity of the water extract of *S. tonkinensis* [91]. Meanwhile, two purified polysaccharide fractions (STRP1 and STRP2) from the roots of *S. tonkinensis* have been reported to attenuate hepatic oxidative damage *in vivo* [95]. In addition, some compounds, including sophocarpine (**34**) from *S. tonkinensis* have been reported to significantly improve liver injury in mice [93].

3.4. Anti-Viral Activity

The compounds isolated from *S. tonkinensis* (Table 2), such as 3-(4-Hydroxyphenyl)-4-(3-methoxy-4-hydroxyphenyl)-3,4-dehydroquinolizidine (**75**), cermizine C (**70**), jussiaeiine A (**68**), jussiaeiine B (**67**), (+)-5 α -hydroxyoxysophocarpine (**17**), (–)-12 β -hydroxyoxysophocarpine (**18**), and (–)-clathrotropine (**64**), have reported the anti-coxsackie virus B₃ (CVB₃) activities with IC₅₀ values rang of 0.12~6.40 μ mol/L [26]. The compounds sophtonseedline B (**188**) and (–)-trifolirhizin (**190**) from *S. tonkinensis* exhibited anti-tobacco mosaic virus (TMV) activities with the inhibition rates of 69.62% and 68.72%, respectively, at a concentration of 100 μ g/mL [56]. The other compounds, including sophtonseedline D (**23**), sophtonseedline F (**8**), and (–)-*N*-formylcytisine (**52**), have been reported to have anti-TMV activities as well [19]. In addition to TMV, compounds (+)-oxysophocarpine (**20**), (–)-sophocarpine (**34**), and (–)-13,14-Dehydrosophoridine (**16**) have showed anti-HBV activities [20].

3.5. Anti-Antioxidant Activities

The antioxidant activities of chloroform, ethyl acetate, *N*-butanol, and ethanol extracts of *S. tonkinensis* have been tested (Table 2). The results of DPPH, ABTS, and OH radical scavenging assay showed that all extracts exhibited antioxidant activities [98]. Some compounds from *S. tonkinensis* exhibited antioxidant activities. It is noteworthy that shandougenine A (**263**), shandougenine C (**127**), shandougenine D (**128**), and 7,4'-Dihydroxyisoflavone (**103**) showed stronger superoxide anion radical scavenging capacity than the known flavanone luteolin. Shandougenines B (**264**) showed DPPH free radical and ABTS cation radical scavenging capacity. Shandougenine A (**263**), shandougenine C (**127**), shandougenine D (**128**), bolusanthin IV (**261**), 2-(2',4'-Dihydroxyphenyl)-5,6-methylenedioxybenzofuran (**260**), and demethylmedicarpin (**179**) were reported parallel ABTS cation radical scavenging capacity to the positive control [40].

3.6. Toxicity

The roots of *S. tonkinensis* were the famous toxic Miao drug (Table 2) and were named Shan Dou Gen or Guang Dou Gen [4,110]. The aqueous and alcoholic parts of *S. tonkinensis* caused obvious liver damage in mice, which could result in both the alteration of liver function and the organelle damage of hepatocytes [111,112]. Meanwhile, the extracts of *S. tonkinensis* exhibited pulmonary toxicity, which may trigger pulmonary cancer, dyspnea, and oxidative stress [113]. The obvious toxicity of sophoranone (**120**) to *zebrafish* was mainly characterized as hepatotoxicity, neurotoxicity, cardiovascular toxicity, and nephrotoxicity in the acute toxicity model [104]. Besides, the alkaloids matrine (**1**), oxymatrine (**4**), cytisine (**50**), and sophocarpine (**34**) of *S. tonkinensis* showed significant cardiotoxicity [114].

3.7. Other Pharmacological Activities

The extracts of *S. tonkinensis* have the ability to reduce blood glucose and resist microbial activities (Table 2, Figure 2). Cytochalasin E (**310**) and H (**306**) inhibit a variety of plant pathogens [71]. The flavonoid-rich extracts of *S. tonkinensis* administrated orally to mice significantly increased sensibility to insulin, as well as reduced fasting blood-glucose levels [33]. Moreover, matrine (**1**) from *S. tonkinensis* could improve glucose metabolism and increased insulin secretion in diabetic mice, which may be used as a potential drug for diabetes treatment [108]. Methanol extracts of *S. tonkinensis* exhibited antidiarrheal activities [115]. Moreover, diverse anti-microbial activities of compounds from *S. tonkinensis* and its endophytic fungi have been reported [26,67].




Figure 2. The biological activities of *S. tonkinensis*.

4. Conclusion and Future Prospective

In this review, we provide a detailed summary of the medicinal chemistry, pharmacological activities, and related toxicity research of *S. tonkinensis*. Structurally, more than 300 compounds have been isolated from *S. tonkinensis* and its endophytic fungi, including alkaloids, triterpenes and triterpenoid saponins, flavonoids, and so on. Some of the star molecules, including matrine (1) and oxymatrine (4), were documented to exhibit well biological activities [110]. For its pharmacological research, previous studies suggested the usage of *S. tonkinensis* in the folk treatment of upper respiratory tract infection diseases. It is generally believed that the alkaloid components of *S. tonkinensis* were the main active substances in the roots of *S. tonkinensis* [116]. Interestingly, the extracts of *S. tonkinensis* have been reported for hepatotoxicity, while the other related studies showed the opposite hepatoprotective effects. The in-depth toxicological or structure-activity relationship study may be worth for further research. Moreover, the roots of *S. tonkinensis* combined with other medicines form dozens of marketing Chinese patent medicine for the treatments of pharyngitis, tonsillitis, and aphthous ulcers [9–11]. However, it is rare for its prescription pharmacological research in the treatment of upper respiratory tract diseases, especially works on the drug combination mechanism, which may need to be further developed.

Author Contributions: Resources, J.-J.L.; writing—original draft preparation, J.-J.L., P.-P.Z., and W.Z.; writing—review and editing, D.S., X.Y., Y.-Q.Z., and X.W.; project administration, X.W., X.P., and Y.Z.; funding acquisition, X.P. and Y.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by National Key Research and Development Program of China (2018YFC1708100), the Guiyang Science and Technology Planning Project (Zhu Ke He [2021]43-11), the National Natural Science Foundation of China (32000276), and the Doctoral Startup Funding of Guizhou University of Traditional Chinese Medicine ([2019]-17).

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wu, C.; He, L.J.; Yi, X.; Qin, J.; Li, Y.L.; Zhang, Y.B.; Wang, G.C. Three new alkaloids from the roots of *Sophora tonkinensis*. *J. Nat. Med.* **2019**, *73*, 667–671. [[CrossRef](#)] [[PubMed](#)]
2. Zhou, Y.Q.; Tan, X.M.; Wu, Q.H.; Ling, Z.Z.; Yu, L.Y. A Survey of Original Plant of Radix et Rhizoma *Sophora tonkinensis* in Guangxi. *Guangxi Sci.* **2010**, *17*, 259–262.
3. Zou, L.; Zhao, H.J.; Li, N.; Zhao, M.Y.; Sun, N.; Song, C. Herbal Textual Research and Toxicity Analysis of Radix *Sophora tonkinensis*. *Mod. Tradit. Chin. Med.* **2021**, *41*, 19–23.
4. Lu, L.F.; Lin, M.Y.; Huang, S.Y.; Yu, Q.R.; Li, T.S. Research Progress of Characteristic National Medicine of Youjiang River Basin in Ethnic Minority Areas. *Chin. J. Exp. Tradit. Med. Formulae.* **2018**, *24*, 191–200.

5. Lan, Y.S.; Yang, R.Y.; Li, Y.; Guan, H.B.; Chu, L.M. The Progress of Research on Chemical Composition and Pharmacological Activity in *Sophora Tonkinensis*. *J. Chuzhou. Univ.* **2010**, *12*, 48–51.
6. Cai, J.; Ma, J.; Xu, K.; Gao, G.; Xiang, Y.; Lin, C. Effect of Radix *Sophora Tonkinensis* on the activity of cytochrome P450 isoforms in rats. *Int. J. Clin. Exp. Med.* **2015**, *8*, 9737–9743. [[PubMed](#)]
7. Li, Y.X.; Wei, H.L. Antitumor Effects of Ethanol Extract of *Sophora tonkinensis* on Lewis Lung Cancer Mice. *J. Shaanxi Univ. Chin. Med.* **2021**, *44*, 86–91.
8. Huang, D.Z.; Zhang, Y.Q. Current and existing problems with the clinical application of *Sophora Tonkinensis*. *Chin. J. Inform. TCM.* **2005**, *12*, 52–53.
9. Sun, J.; Zhao, R.H.; Mao, X.; Guo, S.S.; Gao, Y.J.; Yao, R.M.; Dong, X.; Wu, C.B.; Cui, X.L. Study on the Usage and Dosage of Kaihoujian Spray in the Treatment of Acute Pharyngitis. *World.Chin. Med.* **2019**, *14*, 577–580.
10. Dai, D.; Li, Y.J.; Zhang, J. Clinical Observation of Shuyangqing Spray in Treatment of Acute and Chronic Pharyngitis after Radiotherapy and Chemotherapy. *Chin. Arch. Tradit. Chin. Med.* **2018**, *36*, 908–911.
11. Huang, K.M.; Shen, Y.B. Clinical study of Guilin Xiguashuang in the treatment of accurate pharyngitis. *China J. Tradit. Chin. Med. Pharm.* **2012**, *27*, 2583–2584.
12. He, L.J.; Liu, J.S.; Luo, D.; Zheng, Y.R.; Zhang, Y.B.; Wang, G.C.; Li, Y.L. Quinolizidine alkaloids from *Sophora tonkinensis* and their anti-inflammatory activities. *Fitoterapia* **2019**, *139*, 104391. [[CrossRef](#)]
13. Zhou, M.M.; Fan, Z.Q.; Zhao, A.H.; Zhu, L.; Jia, W. Effects of nonalkaloid fractions of the roots of *Sophora tonkinensis* on mice in an immune induced liver injury model. *Lishizhen Med. Mater. Med. Res.* **2011**, *22*, 2709–2710.
14. Pan, Q.M.; Li, Y.H.; Hua, J.; Huang, F.P.; Wang, H.S.; Liang, D. Antiviral Matrine-Type Alkaloids from the Rhizomes of *Sophora tonkinensis*. *J. Nat. Prod.* **2015**, *78*, 1683–1688. [[CrossRef](#)]
15. Deng, Y.H.; Xu, K.P.; Zhou, Y.J.; Li, F.S.; Zeng, G.Y.; Tan, G.S. A new flavonol from *Sophora tonkinensis*. *J. Asian Nat. Prod. Res.* **2007**, *9*, 45–48. [[CrossRef](#)]
16. Wei, X.; Zhang, W.; Ding, C.F.; Yu, H.F.; Zhang, L.Y.; Zhou, Y. Chemical constituents from the *N*-butanol extract of *Sophora tonkinensis* and their antibacterial activities. *Guihaia* **2021**, *41*, 1054–1060.
17. Liang, S.L. Chemical Constituents from the Aerial Part of *Sophora tonkinensis* and Their Activities. Master's Thesis, Guangxi University, Nanning, China, 2021.
18. Ding, P.L.; Huang, H.; Zhou, P.; Chen, D.F. Quinolizidine alkaloids with anti-HBV activity from *Sophora tonkinensis*. *Planta Med.* **2006**, *72*, 854–856. [[CrossRef](#)]
19. Zou, J.B.; Zhao, L.H.; Yi, P.; An, Q.; He, L.X.; Li, Y.A.; Lou, H.Y.; Yuan, C.M.; Gu, W.; Huang, L.J.; et al. Quinolizidine Alkaloids with Antiviral and Insecticidal Activities from the Seeds of *Sophora tonkinensis* Gagnep. *J. Agric. Food Chem.* **2020**, *68*, 15015–15026. [[CrossRef](#)]
20. Ding, P.L.; Liao, Z.X.; Huang, H.; Zhou, P.; Chen, D.F. (+)-12 alpha-Hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from *Sophora flavescens*. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1231–1235. [[CrossRef](#)]
21. Xiao, P.; Kubo, H.; Komiyama, H.; Higashiyama, K.; Yan, Y.; Li, J.S.; Ohmiya, S. (–)-14β-acetoxymatrine and (+)-14α-acetoxymatrine, two new matrine-type lupin alkaloids from the leaves of *Sophora tonkinensis*. *Chem. Pharm. Bull. (Tokyo)* **1999**, *47*, 448–450. [[CrossRef](#)]
22. Xiao, P.; Li, J.S.; Hajime, K.; Saito, K.; Murakoshi, I.; Ohmiya, S. (–)-14β-Hydroxymatrine, a New Lupine Alkaloid from the Roots of *Sophora tonkinensis*. *Chem. Pharm. Bull.* **1996**, *44*, 1951–1953. [[CrossRef](#)]
23. Tang, Q.; Luo, D.; Lin, D.C.; Wang, W.Z.; Li, C.J.; Zhuo, X.F.; Wu, Z.N.; Zhang, Y.B.; Wang, G.C.; Li, Y.L. Five matrine-type alkaloids from *Sophora tonkinensis*. *J. Nat. Med.* **2021**, *75*, 682–687. [[CrossRef](#)]
24. Pan, Q.M.; Zhang, G.J.; Huang, R.Z.; Pan, Y.M.; Wang, H.S.; Liang, D. Cytisine-type alkaloids and flavonoids from the rhizomes of *Sophora tonkinensis*. *J. Asian Nat. Prod. Res.* **2016**, *18*, 429–435. [[CrossRef](#)]
25. Li, X.N.; Lu, Z.Q.; Qin, S.; Yan, H.X.; Yang, M.; Guan, S.H.; Liu, X.; Hua, H.M.; Wu, L.J.; Guo, D.A. Tonkinensines A and B, two novel alkaloids from *Sophora tonkinensis*. *Tetrahedron Lett.* **2008**, *49*, 3797–3801. [[CrossRef](#)]
26. Yan, Z.; Hu, W.Z.; Chen, X.Z.; Peng, Y.B.; Shi, Y.S. Bioactive quinolizidine alkaloids from *Sophora tonkinensis*. *China J. Chin. Mater. Med.* **2016**, *41*, 2261–2266.
27. Pan, Q.M.; Huang, R.Z.; Pan, Y.M.; Wang, H.S.; Liang, D. Studies on chemical constituents of rhizomes of *Sophora tonkinensis*. *China J. Chin. Mater. Med.* **2016**, *41*, 96–100.
28. Lee, J.W.; Lee, J.H.; Lee, C.; Jin, Q.H.; Lee, D.; Kim, Y.; Hong, J.T.; Lee, M.K.; Hwang, B.Y. Inhibitory constituents of *Sophora tonkinensis* on nitric oxide production in RAW 264.7 macrophages. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 960–962. [[CrossRef](#)]
29. Hu, W.Z.; Hou, M.Y.; Corzo, N.; Olano, A.; Villamiel, M. Phytochemical Constituents of the Rhizomes of *Sophora tonkinensis*. *Indian J. Pharm. Sci.* **2018**, *111*, 8–9.
30. Cheng, Q.; Wang, J.F.; Wang, B.L.; Dai, Y.H.; Xu, K.X.; Jia, Z.Y.; Li, P.; Ma, Z.Q.; Lin, R.C. Research Progress in Chemical Components, Bioactivity and Quality Control of Radix et Rhizoma *Sophora Tonkinensis*. *J. Liaoning Univ. Tradit. Chin. Med.* **2017**, *19*, 119–125.
31. Hou, M.Y.; Hu, W.Z.; Hao, K.X.; Xiu, Z.L. Flavonoids and phenolic acids from the roots of *Sophora tonkinensis* Gagnep. *Biochem. Syst. Ecol.* **2020**, *89*, 104011. [[CrossRef](#)]
32. Shirataki, Y.; Yokoe, I.; Komatsu, M. Two New Flavone Glycosides from the Roots of *Sophora subprostrata*. *J. Nat. Prod.* **1986**, *49*, 645–649. [[CrossRef](#)]

33. Huang, M.; Deng, S.H.; Han, Q.Q.; Zhao, P.; Zhou, Q.; Zheng, S.J.; Ma, X.H.; Xu, C.; Yang, J.; Yang, X.Z. Hypoglycemic Activity and the Potential Mechanism of the Flavonoid Rich Extract from *Sophora tonkinensis* Gagnep. in KK-Ay Mice. *Front. Pharmacol.* **2016**, *7*, 288. [[CrossRef](#)]
34. Xia, W.J.; Luo, P.; Hua, P.; Ding, P.; Li, C.J.; Xu, J.; Zhou, H.H.; Gu, Q. Discovery of a New Pterocarpan-Type Antineuroinflammatory Compound from *Sophora tonkinensis* through Suppression of the TLR4/NF kappa B/MAPK Signaling Pathway with PU.1 as a Potential Target. *ACS Chem. Neurosci.* **2019**, *10*, 295–303. [[CrossRef](#)]
35. Li, X.G.; Yan, H.X.; Pang, X.Y.; Sha, N.; Hua, H.M.; Wu, L.J.; Guo, D.A. Chemical constituents of flavonoids from rhizome of *Sophora tonkinensis*. *China J. Chin. Mater. Med.* **2009**, *34*, 282–285.
36. He, C.M.; Cheng, Z.H.; Chen, D.F. Qualitative and quantitative analysis of flavonoids in *Sophora tonkinensis* by LC/MS and HPLC. *Chin. J. Nat. Med.* **2013**, *11*, 690–698. [[CrossRef](#)]
37. Jin, X.; Lu, Y.; Chen, S.X.; Chen, D.F. UPLC-MS identification and anticomplement activity of the metabolites of *Sophora tonkinensis* flavonoids treated with human intestinal bacteria. *J. Pharm. Biomed. Anal.* **2020**, *184*, 113176. [[CrossRef](#)]
38. Yang, R.Y.; Lan, Y.S.; Huang, Z.J.; Shao, C.L.; Liang, H.; Chen, Z.F.; Li, J. Isoflavonoids from *Sophora tonkinensis*. *Chem. Nat. Compd.* **2012**, *48*, 674–676. [[CrossRef](#)]
39. Zhang, W.; Wei, X.; Zhang, L.Y.; Hu, X.Y.; Zhou, Y.Q.; Zhou, Y. Chemical constituents of *Sophora tonkinensis*. *Chem. Nat. Compd.* **2020**, *56*, 1140–1142. [[CrossRef](#)]
40. Luo, G.Y.; Yang, Y.; Zhou, M.; Ye, Q.; Liu, Y. Novel 2-arylbenzofuran dimers and polyisoprenylated flavanones from *Sophora tonkinensis*. *Fitoterapia* **2014**, *99*, 21–27. [[CrossRef](#)]
41. Ding, P.L.; Chen, D.F. Study on phenolic constituents of the *Sophora tonkinensis*. *Chin. Tradit. Herb. Drugs.* **2008**, *39*, 186–188.
42. Ahn, J.M.; Kim, Y.M.; Chae, H.S.; Choi, Y.H.; Ahn, H.C.; Yoo, H.; Kang, M.; Kim, J.; Chin, Y.W. Prenylated flavonoids from the roots and rhizomes of *Sophora tonkinensis* and their effects on the expression of inflammatory mediators and proprotein convertase subtilisin/kexin type 9. *J. Nat. Prod.* **2019**, *82*, 309–317. [[CrossRef](#)] [[PubMed](#)]
43. Yang, B.Y.; He, R.J.; Wang, Y.F.; Huang, Y.L. Chemical constituents from the aerial part of *Sophora tonkinensis* and their tyrosinase inhibitory activity. *Guihaia* **2022**. [[CrossRef](#)]
44. Yang, R.Y.; Lan, Y.S.; Huang, Z.J.; Shao, C.L.; Liang, H.; Chen, Z.F.; Li, J. A New Isoflavonolignan Glycoside from the Roots of *Sophora tonkinensis*. *Rec. Nat. Prod.* **2012**, *6*, 212–217.
45. Chae, H.S.; Yoo, H.; Kim, Y.M.; Choi, Y.H.; Lee, C.H.; Chin, Y.W. Anti-inflammatory effects of 6,8-diprenyl-7,4'-dihydroxyflavanone from *Sophora tonkinensis* on lipopolysaccharide-stimulated RAW 264.7 cells. *Molecules* **2016**, *21*, 1049. [[CrossRef](#)]
46. Li, X.N.; Sha, N.; Yan, H.X.; Pang, X.Y.; Guan, S.H.; Yang, M.; Hua, H.M.; Wu, L.J.; Guo, D.A. Isoprenylated flavonoids from the roots of *Sophora tonkinensis*. *Phytochem. Lett.* **2008**, *1*, 163–167. [[CrossRef](#)]
47. Yoo, H.; Chae, H.S.; Kim, Y.M.; Kang, M.; Ryu, K.H.; Ahn, H.C.; Yoon, K.D.; Chin, Y.W.; Kim, J. Flavonoids and arylbenzofurans from the rhizomes and roots of *Sophora tonkinensis* with IL-6 production inhibitory activity. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 5644–5647. [[CrossRef](#)]
48. Yang, X.Z.; Deng, S.H.; Huang, M.; Wang, J.L.; Chen, L.; Xiong, M.R.; Yang, J.; Zheng, S.J.; Ma, X.H.; Zhao, P.; et al. Chemical constituents from *Sophora tonkinensis* and their glucose transporter 4 translocation activities. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 1463–1466. [[CrossRef](#)]
49. Wang, W.; Nakashima, K.-I.; Hirai, T.; Inoue, M. Neuroprotective effect of naturally occurring RXR agonists isolated from *Sophora tonkinensis* Gagnep. on amyloid- β -induced cytotoxicity in PC12 cells. *J. Nat. Med.* **2019**, *73*, 154–162. [[CrossRef](#)]
50. Ding, P.L.; Chen, D.F. Three cyclized isoprenylated flavonoids from the roots and rhizomes of *Sophora tonkinensis*. *Helv. Chim. Acta* **2007**, *90*, 2236–2244. [[CrossRef](#)]
51. Inoue, M.; Tanabe, H.; Nakashima, K.; Ishida, Y.; Kotani, H. Reginoids Isolated from *Sophora tonkinensis* with a Gene Expression Profile Distinct from the Synthetic Reginoid Bexarotene. *J. Nat. Prod.* **2014**, *77*, 1670–1677. [[CrossRef](#)]
52. Li, X.N.; Lu, Z.Q.; Chen, G.T.; Yan, H.X.; Sha, N.; Guan, S.H.; Yang, M.; Hua, H.M.; Wu, L.; Guo, D.A. NMR spectral assignments of isoprenylated flavanones from *Sophora tonkinensis*. *Magn. Reson. Chem.* **2008**, *46*, 898–902. [[CrossRef](#)]
53. Ding, P.L.; Chen, D.F. Isoprenylated flavonoids from the roots and rhizomes of *Sophora tonkinensis*. *Helv. Chim. Acta* **2006**, *89*, 103–110. [[CrossRef](#)]
54. He, C.M. Comparative Studies on Flavonoids and Their Bioactivities of *Sophora flavescens* and *Sophora tonkinensis*. Ph.D. Thesis, Fudan University, Shanghai, China, 2010.
55. Park, J.A.; Kim, H.J.; Jin, C.; Lee, K.T.; Yong, S.L. A new pterocarpan, (–)-maackiain sulfate, from the roots of *Sophora subprostrata*. *Arch. Pharm. Res.* **2003**, *26*, 1009–1013. [[CrossRef](#)]
56. Hu, Z.X.; Zou, J.B.; An, Q.; Yi, P.; Yuan, C.M.; Gu, W.; Huang, L.J.; Lou, H.Y.; Zhao, L.H.; Hao, X.J. Anti-tobacco mosaic virus (TMV) activity of chemical constituents from the seeds of *Sophora tonkinensis*. *J. Asian Nat. Prod. Res.* **2021**, *23*, 644–651. [[CrossRef](#)]
57. Chae, H.S.; Yoo, H.; Choi, Y.H.; Choi, W.J.; Chin, Y.W. Maackiapterocarpan B from *Sophora tonkinensis* Suppresses Inflammatory Mediators via Nuclear Factor- κ B and Mitogen-Activated Protein Kinase Pathways. *Biol. Pharm. Bull.* **2016**, *39*, 259–266. [[CrossRef](#)]
58. Li, X.N. Chemical Constituents of *Sophora tonkinensis* and Fragmentation Patterns of the Flavonoids in ESI Mass Spectrometry. Ph.D. Thesis, Shenyang Pharmaceutical University, Shenyang, China, 2009.
59. Takeshita, T.; Yokoyama, K.; Yi, D.; Kinjo, J.; Nohara, T. Four new and twelve known saponins from *Sophora subprostrata* Radix. *Chem. pharm. bull.* **1991**, *39*, 1908–1910. [[CrossRef](#)]

60. Long, J.Q.; Lin, H.; Yang, X.D.; Zhao, J.F.; Liang, L.I. Study on the chemical constituents of *Sophora tonkinensis* from Guangxi. *J. Yunnan Univ. Nat. Sci. Ed.* **2011**, *33*, 72–76.
61. Ding, Y.; Takeshita, T.; Yokoyama, K.; Kinjo, J.; Nohara, T. Triterpenoid Glycosides from *Sophora Subprostratae* Radix. *Chem. Pharm. Bull.* **1992**, *40*, 139–142. [[CrossRef](#)]
62. Sakamoto, S.; Kuroyanagi, M.; Ueno, A.; Sekita, S. Triterpenoid saponins from *Sophora subprostrata*. *Phytochemistry* **1992**, *31*, 1339–1342. [[CrossRef](#)]
63. Ding, Y.; Tian, R.H.; Takeshita, T.; Kinjo, J.; Nohara, T. Four new oleanene glycosides from *Sophora Subprostratae* Radix. III. *Chem. Pharm. Bull.* **1992**, *40*, 1831–1834. [[CrossRef](#)]
64. He, H.K.; Sun, H.; Yang, S.L.; Tian, M.Y.; Wang, S.J. Studies on active aromatic constituents from rhizomes of *Sophora tonkinensis*. *China J. Chin. Mater. Med.* **2019**, *44*, 4481–4485.
65. Mo, T.X.; Liu, X.B.; Duan, L.H.; Zhang, X.M.; Xu, Z.L.; Qin, X.Y.; Li, B.C.; Li, J.; Yang, R.Y. secondary metabolites of the endophytic fungus *Xylaria* sp. GDG-102 from *Sophora tonkinensis*. *Chem. Nat. Compd.* **2021**, *57*, 764–766. [[CrossRef](#)]
66. Xu, Z.L.; Cao, S.M.; Qin, Y.Y.; Mo, T.X.; Li, B.C.; Qin, X.Y.; Huang, X.S.; Li, J.; Yang, R.Y. Chemical Constituents of the Endophytic Fungus *Penicillium macrosclerotiorum* from *Sophora tonkinensis*. *Chem. Nat. Compd.* **2021**, *57*, 542–544. [[CrossRef](#)]
67. Zheng, N.; Yao, F.H.; Liang, X.F.; Liu, Q.; Xu, W.F.; Liang, Y.; Liu, X.B.; Li, J.; Yang, R.Y. A new phthalide from the endophytic fungus *Xylaria* sp. GDG-102. *Nat. Prod. Res.* **2018**, *32*, 755–760. [[CrossRef](#)] [[PubMed](#)]
68. Liang, Y.; Xu, W.F.; Liu, C.M.; Zhou, D.X.; Liu, X.B.; Qin, Y.Y.; Cao, F.; Li, J.; Yang, R.Y.; Qin, J.K. Eremophilane sesquiterpenes from the endophytic fungus *Xylaria* sp. GDG-102. *Nat. Prod. Res.* **2019**, *33*, 1304–1309. [[CrossRef](#)]
69. Qin, Y.Y.; Liu, X.B.; Lin, J.; Huang, J.Y.; Jiang, X.F.; Mo, T.X.; Xu, Z.L.; Li, J.; Yang, R.Y. Two new phthalide derivatives from the endophytic fungus *Penicillium vulpinum* isolated from *Sophora tonkinensis*. *Nat. Prod. Res.* **2021**, *35*, 421–427. [[CrossRef](#)]
70. Xu, W.F.; Hou, X.M.; Yao, F.H.; Zheng, N.; Li, J.; Wang, C.Y.; Yang, R.Y.; Shao, C.L. Xylapeptide A, an Antibacterial Cyclopentapeptide with an Uncommon L-Pipecolic Acid Moiety from the Associated Fungus *Xylaria* sp. (GDG-102). *Sci. Rep.* **2017**, *7*, 6937. [[CrossRef](#)]
71. Huang, X.S.; Zhou, D.X.; Liang, Y.; Liu, X.B.; Cao, F.; Qin, Y.Y.; Mo, T.X.; Xu, Z.L.; Li, J.; Yang, R.Y. Cytochalasins from endophytic *Diaporthe* sp. GDG-118. *Nat. Prod. Res.* **2019**, *35*, 3396–3403. [[CrossRef](#)] [[PubMed](#)]
72. Qin, Y.Y.; Liu, X.B.; Mo, T.X.; Li, J.; Yang, R.Y. Secondary Metabolites of Endophytic Fungus *Xylaria* sp. GDGJ-368 from *Sophora tonkinensis*. *J. Guangxi. Nor. Univ. Nat. Sci. Ed.* **2020**, *38*, 71–77.
73. Ding, P.L.; Yu, Y.Q.; Chen, D.F. *Comparative Studies on the Chemical Constituents of Sophora tonkinensis and Sophora flavescens*, 7th China Doctoral Forum for New Medicines, Nanchang, Jiangxi, China; China Academic Journal Electronic Publishing House: Nanchang, China, 2004; pp. 30–32.
74. Li, F.; Li, C.P.; Fu, H.; Su, X.L.; Wang, Z.J.; Hou, X.R.; Lin, R.C.; Guan, X.Y.; Liu, Q.M. Research progress of Radix *Sophora Tonkinensis* and supplementary reports of assay method for toxic chemical composition. *Chin. J. Pharm. Anal.* **2013**, *33*, 1453–1463.
75. Ai, H.; Sun, J.; Sheng, Y.H.; Ning, L.; Tang, L.M.; Jin, R.M. Study on anti-inflammation mechanism of Radix et Rhizome *Sophora tonkinensis* rat based on profile of pharmacokinetic parameters. *Chin. Pharmacol. Bull.* **2020**, *36*, 645–649.
76. Yoo, H.; Kang, M.; Pyo, S.; Chae, H.S.; Ryu, K.H.; Kim, J.; Chin, Y.W. SKI3301, a purified herbal extract from *Sophora tonkinensis*, inhibited airway inflammation and bronchospasm in allergic asthma animal models *in vivo*. *J. Ethnopharmacol.* **2017**, *206*, 298–305. [[CrossRef](#)] [[PubMed](#)]
77. Peng, H.H.; Huang, J.; Wen, X.I.; Ping, L.I.; Jiang, H.Y. Anti-inflammatory Effect and Related Mechanism of *Sophora tonkinensis* Granula and its Herbal Piece. *Chin. J. Exp. Tradit. Med. Formulae.* **2013**, *19*, 265–269.
78. Qian, L.W.; Dai, W.H.; Zhou, G.Q.; Wang, L.L.; Wang, H.S. Antinociceptive and anti-inflammatory effects of major alkaloids from the roots of radix *sophora flavescens* and Radix *Sophora tonkinensis*. *Chin. Tradit. Pat. Med.* **2012**, *34*, 1593–1596.
79. Lu, X.P.; Zhou, H.S.; Xi, W.; Wei, L.; Li, P. Study on anti-inflammatory effect of Shandougen Keli. *Inn. Mongolia. J. Tradit. Chin. Med.* **2011**, *30*, 85–86.
80. Luan, Y.F.; Luo, D.; Zheng, L.N.; Xie, Y.Z.; Sun, R. The Margin of Safety Study on Anti-inflammatory Effect of Different Components from Radix et Rhizome *Sophora Tonkinensis*. *Chin. J. Pharmacovigil.* **2012**, *9*, 392–396.
81. Li, X.Y.; Sun, R. Study on Mechanisms of Anti-inflammatory Efficacy Accompanied by Toxicity and Side Effects of Water Extraction Components of *Sophora Tonkinensis* Radix et Rhizoma on Throat Excess-heat Syndrome Mice. *Chin. J. Pharmacovigil.* **2015**, *12*, 82–85.
82. Chui, C.H.; Lau, F.Y.; Tang, J.C.O.; Kan, K.L.; Cheng, G.Y.M.; Wong, R.S.M.; Kok, S.H.L.; Lai, P.B.S.; Ho, R.; Gambari, R. Activities of fresh juice of *Scutellaria barbata* and warmed water extract of Radix *Sophora Tonkinensis* on anti-proliferation and apoptosis of human cancer cell lines. *Int. J. Mol. Med.* **2005**, *16*, 337–341.
83. Deng, Y.H.; Sun, L.; Zhang, W.; Xu, K.P.; Li, F.S.; Tan, J.B.; Cao, J.G.; Tan, G.S. Studies on Cytotoxic Constituents from *Sophora tonkinensis*. *Nat. Prod. Res. Dev.* **2006**, *3*, 408–410.
84. Chen, Y.; Zhang, Q.; Han, S.X.; Han, F.M.; Chen, L.M.; Tong, Y.; You, Y. Studies on the toxic effects of different extraction sites from Radix *Sophora tonkinensis*. *Chin. J. Pharmacovigil.* **2017**, *14*, 188–189.
85. Huang, Z.R. Exploration of an effective and safety method for the quality control of *Sophora tonkinensis* radix et rhizome. Master's Thesis, Xi'an University of Technology, Shaanxi, China, 2021.
86. Li, J.L.; Zhang, D.; Liu, S. Effect of *Sophora Tonkinensis* Gapnep. on Growth and Proliferation of Murine Melanoma Cell B16-BL6. *Guangming. J. Chin. Med.* **2017**, *32*, 1256–1259.

87. Wang, S.; Song, Z.J.; Gong, X.M.; Ou, C.L.; Zhang, W.Y.; Wang, J.; Yao, C.Y.; Qin, S.S.; Yan, B.X.; Li, Q.P.; et al. Chloroform extract from *Sophora tonkinensis* Gagnep. inhibit proliferation, migration, invasion and promote apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway. *J. Ethnopharmacol.* **2021**, *271*, 113879.
88. Kajimoto, S.; Takanashi, N.; Kajimoto, T.; Xu, M.; Cao, J.D.; Masuda, Y.; Aiuchi, T.; Nakajo, S.; Ida, Y.; Nakaya, K. Sophoranone, extracted from a traditional Chinese medicine Shan Dou Gen, induces apoptosis in human leukemia U937 cells via formation of reactive oxygen species and opening of mitochondrial permeability transition pores. *Int. J. Cancer* **2002**, *99*, 879–890. [[CrossRef](#)]
89. Yao, Z.Q.; Zhu, H.; Wang, G.F. Anti-tumor Effect of Total Alkaloids of Radix *Sophora tonkinensis*. *J. Nanjing. Univ. Tradit. Chin. Med.* **2005**, *21*, 253–254.
90. Cao, L.; Li, T.J.; Meng, X.S.; Bao, Y.R.; Wang, S. Study on the Efficacy and Mechanism of Liver Cancer Induced by DEN in Rats of Alkaloids of *Sophora Tonkinensis* Radix Et Rhizoma. *Chin. J. Mod. Appl. Pharm.* **2018**, *35*, 370–374.
91. Zhao, Q.; Wei, M.; Zhang, S.; Huang, Z.; Ji, L. The water extract of *Sophora tonkinensis* Radix et Rhizoma alleviates non-alcoholic fatty liver disease and its mechanism. *Phytomedicine* **2020**, *77*, 153270. [[CrossRef](#)]
92. Yin, L.S.; Lv, L.L.; Dou, L.W.; Li, X.Y.; Sun, R. Study on Anti-inflammatory Efficacy Accompanied by Toxicity and Side Effects of Water Extraction Components of *Sophora Tonkinensis* Radix et Rhizoma on Throat Excess-heat Syndrome Mice. *Chin. J. Pharmacovigil.* **2015**, *12*, 79–81+85.
93. Huang, Y.Q. The Intervention of Major Alkaloids in *Sophora tonkinensis* on Immune Liver Injury in Mice. Master's Thesis, Chengdu University of TCM, Chengdu, China, 2017.
94. Han, Y.Z. Preliminary study on the protective effect and mechanism of oxymatrine on Con A-induced liver injury in mice. Master's Thesis, Chengde Medical University, Sichuan, China, 2016.
95. Cai, L.L.; Zou, S.S.; Liang, D.P.; Luan, L.B. Structural characterization, antioxidant and hepatoprotective activities of polysaccharides from *Sophora tonkinensis* Radix. *Carbohydr. Polym.* **2018**, *184*, 354–365. [[CrossRef](#)]
96. Wang, L.P.; Lu, J.Y.; Sun, W.; Gu, Y.M.; Zhang, C.C.; Jin, R.M.; Li, L.Y.; Zhang, Z.A.; Tian, X.S. Hepatotoxicity induced by radix *Sophora tonkinensis* in mice and increased serum cholinesterase as a potential supplemental biomarker for liver injury. *Exp. Toxicol. Pathol.* **2017**, *69*, 193–202. [[CrossRef](#)]
97. Kim, H.Y.; Shin, H.S.; Park, H.; Kim, Y.C.; Yong, G.Y.; Sun, P.; Shin, H.J.; Kim, K. In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex. *J. Clin. Virol.* **2008**, *41*, 122–128. [[CrossRef](#)]
98. Xu, H.T.; Lu, J.F.; Zhao, Y.Z.; Zhou, J.Y. Antioxidant and antibacterial activity of extracts from *Sophora tonkinensis* Gagnep. *Sci. Technol. Food Ind.* **2015**, *36*, 111–114.
99. Ning, X.; Liu, Y.; Jia, M.; Wang, Q.; Sun, L. Pectic polysaccharides from Radix *Sophora Tonkinensis* exhibit significant antioxidant effects. *Carbohydr. Polym.* **2021**, *262*, 117925. [[CrossRef](#)]
100. Peng, T.; Su, L.J.; Hu, T.J.; Shuai, X.H. Acute toxicity test of ethanol extract from the radix et rhizome of *Sophora tonkinensis* Gagnep. *Guangxi. J. Anim. Husbandry.* **2010**, *26*, 5–7.
101. Fan, H.T.; Gu, Y.M.; Sun, W.; Geng, Y.; Wang, L.P.; Jin, R.M.; Zhang, Z.A.; Tian, X.S. Effect of Cytisine on Hepatotoxicity of *Sophora tonkinensis* Radix et Rhizoma. *Chin. J. Exp. Tradit. Med. Formulae.* **2018**, *24*, 176–181.
102. Sun, R.; Yang, Q.; Zhao, Y. Comparative Study on Acute Toxicity of Different Components of Radix et Rhizome *Sophora tonkinensis* in Mice. *Chin. J. Pharmacovigil.* **2010**, *7*, 257–262.
103. Wang, P.; Wu, X.; Li, J.P.; Xie, T.Z.; Wu, X.O.; Wang, X.W.; Wen, P.; Zhan, H.Q.; Li, J. Study on Acute Toxicity of Radix et Rhizome *Sophora tonkinensis*. *Lishizhen Med. Mater. Med. Res.* **2013**, *24*, 771–773.
104. Yuan, W.L.; Huang, Z.R.; Xiao, S.J.; Zhang, W.D.; Shen, Y.H. Acute toxicity study of flavonoids from *Sophora Tonkinensis* Radix et Rhizoma on zebrafish. *Chin. Tradit. Herb. Drugs.* **2021**, *52*, 2978–2986.
105. Liu, H.C.; Zhu, X.Y.; Chen, J.H.; Guo, S.Y.; Li, C.Q.; Deng, Z.P. Toxicity comparison of different active fractions extracted from radix *Sophora tonkinensis* in zebrafish. *J. Zhejiang. Univ. Sci. B.* **2017**, *18*, 757–769. [[CrossRef](#)]
106. Zheng, N.; Liu, Q.; He, D.L.; Liang, Y.; Li, J.; Yang, R.Y. A New Compound from the Endophytic Fungus *Xylaria sp* from *Sophora tonkinensis*. *Chem. Nat. Compd.* **2018**, *54*, 447–449. [[CrossRef](#)]
107. Yao, Y.Q.; Wang, D.K.; Li, L.B.; Huang, R.S.; Lan, F. Antifungal Activity of Methanol Extracts from the Root of *Sophora tonkinensis* Gagnep against Main Pathogenic Fungi of *Panax notoginseng*. *Genom. Appl. Biol.* **2016**, *35*, 2417–2422.
108. Guo, S.; Yan, T.; Shi, L.; Liu, A.; Zhang, T.; Xu, Y.; Jiang, W.; Yang, Q.; Yang, L.; Liu, L.N.; et al. Matrine, as a CaSR agonist promotes intestinal GLP-1 secretion and improves insulin resistance in diabetes mellitus. *Phytomedicine* **2021**, *84*, 153507. [[CrossRef](#)] [[PubMed](#)]
109. Wang, Z.; Wang, D.; Liu, A.; Huang, L. Analysis of Chemical Constituents of Effective Part of Anti-butyrylcholinesterase of *Sophora tonkinensis* by UPLC-Q-TOF-MS. *Mod. Chin. Med.* **2015**, *17*, 912–916.
110. Zhou, S.Y.; Chen, J.P.; Liu, Z.D.; Zhou, J.R.; Liu, Y.; Liu, S.X.; Tian, C.W.; Chen, C.Q. Research progress on chemical constituents and pharmacological effects of *Sophora tonkinensis* Radix et Rhizoma. *Chin. Tradit. Herb. Drugs.* **2021**, *52*, 1510–1521.
111. Li, S.J.; Qian, X.L.; Li, X.Y.; Huang, W.; Sun, R. Research of Hepatotoxic Damage Caused by Different Components of Radix et Rhizoma *Sophora Tonkinensis*. *Chin. J. Pharmacovigil.* **2011**, *8*, 577–580.
112. Li, S.J.; Lv, L.L.; Qian, X.L.; Li, X.Y.; Sun, R. Experimental Study on the “Dose-Time-Toxicity” Relationship of Hepatotoxicity Induced by Different Components from Radix et Rhizoma *Sophora Tonkinensis* in Mice. *Chin. J. Pharmacovigil.* **2011**, *8*, 81–84.

113. Zhang, S.N.; Li, X.Z.; Yang, W.D.; Zhou, Y. *Sophora tonkinensis* radix et rhizome-induced pulmonary toxicity: A study on the toxic mechanism and material basis based on integrated omics and bioinformatics analyses. *J. Chromatogr. B* **2021**, *1179*, 122868. [[CrossRef](#)]
114. Wang, R.; Wang, M.; Wang, S.; Yang, K.; Zhou, P.; Xie, X.H.; Cheng, Q.; Ye, J.X.; Sun, G.B. An integrated characterization of contractile, electrophysiological, and structural cardiotoxicity of *Sophora tonkinensis* Gapnep. in human pluripotent stem cell-derived cardiomyocytes. *Stem Cell. Res. Ther.* **2019**, *10*, 1–15. [[CrossRef](#)]
115. Li, Y.Y.; Li, J.; Liu, X.; Zhang, J.W.; Mei, X.; Zheng, R.D.; Chen, W.; Zheng, Q.; Zhong, S.J. Antidiarrheal activity of methanol extract of *Sophora tonkinensis* in mice and spasmolytic effect on smooth muscle contraction of isolated jejunum in rabbits. *Pharm. Biol.* **2019**, *57*, 477–484. [[CrossRef](#)]
116. Dai, W.H.; Qian, L.W.; Yang, S.Y.; Zhou, G.Q. Advance in pharmaceutical research of main alkaloid in *Sophora flavescens* and *Sophora tonkinensis*. *Anhui Med. Pharm. J.* **2011**, *15*, 1057–1060.